Iodine-124: A Promising Positron Emitter for Organic PET Chemistry

Koehler, Lena; Gagnon, Katherine; McQuarrie, Steve; Wuest, Frank

doi:10.3390/molecules15042686

Open AccessReview

Iodine-124: A Promising Positron Emitter for Organic PET Chemistry

by

Lena Koehler

^1,,

Katherine Gagnon

^2,,

Steve McQuarrie

³ and

Frank Wuest

^3,*

¹

Institute of Radiopharmacy, Research Center Dresden-Rossendorf, Dresden, Germany

²

Department of Physics, University of Alberta, Edmonton, Canada

³

Department of Oncology, University of Alberta, Edmonton, Canada

^*

Author to whom correspondence should be addressed.

These two authors contributed equally to this work.

Molecules 2010, 15(4), 2686-2718; https://doi.org/10.3390/molecules15042686

Submission received: 5 March 2010 / Revised: 7 April 2010 / Accepted: 9 April 2010 / Published: 13 April 2010

(This article belongs to the Special Issue Organic Iodine Chemistry)

Download

Browse Figures

Versions Notes

Abstract

:

The use of radiopharmaceuticals for molecular imaging of biochemical and physiological processes in vivo has evolved into an important diagnostic tool in modern nuclear medicine and medical research. Positron emission tomography (PET) is currently the most sophisticated molecular imaging methodology, mainly due to the unrivalled high sensitivity which allows for the studying of biochemistry in vivo on the molecular level. The most frequently used radionuclides for PET have relatively short half-lives (e.g. ¹¹C: 20.4 min; ¹⁸F: 109.8 min) which may limit both the synthesis procedures and the time frame of PET studies. Iodine-124 (¹²⁴I, t_1/2= 4.2 d) is an alternative long-lived PET radionuclide attracting increasing interest for long term clinical and small animal PET studies. The present review gives a survey on the use of ¹²⁴I as promising PET radionuclide for molecular imaging. The first part describes the production of ¹²⁴I. The second part covers basic radiochemistry with ¹²⁴I focused on the synthesis of ¹²⁴I-labeled compounds for molecular imaging purposes. The review concludes with a summary and an outlook on the future prospective of using the long-lived positron emitter ¹²⁴I in the field of organic PET chemistry and molecular imaging.

Keywords:

iodine-124; positron emission tomography (PET); molecular imaging

1. Introduction

The convergence of molecular and cellular biology with imaging sciences to molecular imaging has revolutionized current biomedical research. Molecular imaging is defined as the in vivo characterization and measurement of biologic processes at the cellular and molecular level [1,2,3]. Molecular imaging aims at developing non-invasive strategies for characterizing the molecular and metabolic profiling in living subjects. Molecular and cellular processes can be studied and visualized at various levels of resolution by means of in vivo imaging techniques, which span from ultrasonic to gamma-ray frequencies. In recent years, positron emission tomography (PET) has become a powerful non-invasive molecular imaging technique which provides functional information of physiological, biochemical and pharmacological processes in laboratory animals and humans [4,5,6]. The possibility to observe molecular interactions in living organisms and to determine absolute values of physiological parameters places PET in a unique position among other molecular imaging techniques. In a typical PET study the PET radiotracer, a compound labeled with a short-lived positron emitter, is injected intravenously into a human or animal. Tissue concentrations of the radiotracer are measured over time, and these data are combined with information on plasma probe concentration of the radiotracer to assay metabolism. Mathematical methods for the evaluation of PET measurements within the framework of compartment models are well established [7,8]. Within the spectrum of available positron emitters, fluorine-18 (¹⁸F) is an almost ideal radionuclide for PET, thanks to its ease of production and favorable physical properties, such as a 109.8 min half-life and low β⁺ energy (0.64 MeV). The success of various ¹⁸F-labeled radiotracers like 2-[¹⁸F]fluoro-2-deoxy-D-glucose ([¹⁸F]-FDG) as metabolic markers in biomedical research and clinical practice has prompted research on the potential of other positron-emitting radionuclides with longer half-lives. The choice of the appropriate radionuclide is among the most important aspects for the design and application of novel PET radiotracers. The physical half-life of the radionuclide should reflect the timeframe of the biological process to be studies. Various excellent reviews have addressed and discussed the importance of other positron-emitting radionuclides in the design of novel radiopharmaceuticals [9,10,11].

Several other positron emitting radionuclides with different physical half-lives can be prepared in high yields by means of small biomedical cyclotrons. Prominent examples of positron-emitting radionuclides with longer half-lives include copper-64 (⁶⁴Cu, t_1/2 = 12.7 h), yttrium-86 (⁸⁶Y, t_1/2 = 14.7 h), bromine-76 (⁷⁶Br, t_1/2 = 16.2 h), and iodine-124 (¹²⁴I, t_1/2 = 4.2 d).

In recent years, the positron emitting halogen ¹²⁴I has become an attractive long-lived radionuclide for the design and synthesis of novel PET radiotracers. Its convenient 4.2 d half-life allows extended radiosynthesis protocols and longitudinal PET imaging studies. Moreover, labeling chemistry for ¹²⁴I is well established, and a wide variety of compounds have been labeled for molecular imaging purposes with PET.

The present review gives a survey on the use of ¹²⁴I as promising PET radionuclide for molecular imaging. The first part of the review deals with the production, processing and PET imaging of ¹²⁴I. The second part covers basic radiochemistry with ¹²⁴I focused on the synthesis of ¹²⁴I-labeled compounds for molecular imaging purposes. The review concludes with a summary and an outlook on the future prospective of using the long-lived positron emitter ¹²⁴I in the field of organic PET chemistry and molecular imaging.

2. Production, processing, and PET imaging of ¹²⁴I

2.1. ¹²⁴I production routes

Early investigations into the production of ¹²⁴I most commonly employed the ¹²⁴Te(d,2n)¹²⁴I nuclear reaction scheme [12,13,14,15,16]. More recently however, with the increase in the number of low-energy proton cyclotrons (for the purpose of producing traditional PET isotopes such as ¹⁸F or ¹¹C), the ¹²⁴Te(p,n)¹²⁴I reaction has been gaining popularity [15,17,18,19,20,21]. Despite the slight decrease in yields noted with the ¹²⁴Te(p,n)¹²⁴I nuclear reaction (Table 1), this scheme offers the possibility of obtaining the highest levels of ¹²⁴I radioiodine purity at the time of administration.

Table 1. Selection of published data on ¹²⁴I production.

**Table 1.** Selection of published data on ¹²⁴I production.
Nuclear reaction	Effective Energy [MeV]	Targetmaterial	Enrichment [%]	Yield [MBq/μAh]	Radioiodine impurities [%]	Reference
¹²⁴Te(p,n)¹²⁴I	13→9	Te	99.51	20^a	¹²³I(41)	[17]
	12.2→0	TeO₂	99.8	13	¹²³I(10.039), ¹²⁵I(0.018), ¹²⁶I(0.041), ¹³⁰I(0.379)	[15]
	13.5→9	TeO₂/ 5% Al₂O₃	99.8	5.8	¹²⁵I(0.01), ¹²⁶I(<0.0001)	[18]
	12.5→5	TeO₂	99.3	9.0 ± 1.0	¹²⁵I(0.053 ± 0.015)	[19]
	11→2.5	TeO₂/ 6% Al₂O₃	99.5	6.40 ± 0.44	¹²⁵I(<0.02), ¹²⁶I(<0.001)	[20]
	14→7	TeO₂/ 5% Al₂O₃	99.86	21.1	¹²⁵I(0.03), ¹²⁶I(0.007)	[21]
¹²⁵Te(p,2n)¹²⁴I	20.1→10.5	TeO₂	93	43.3	¹²³I(8), ¹²⁵I(5)	[25]
	22→4	Te	98.3	111^a	¹²⁵I(0.89)	[26]
	21→15	Te	98.3	81^a	¹²³I(7.4), ¹²⁵I(0.9)	[24]
	22	TeO₂	98.5	104	¹²³I(<1)	[27]
¹²⁶Te(p,3n)¹²⁴I	36.8→33.6	Te	Nat	67 ^a	--	[28]
	38→28	Te	> 98	148^a	¹²³I(84), ¹²⁵I(1.5), ¹²⁶I(1.4)	[29]
¹²³Te(d,n)¹²⁴I	11→6	Te	91.0, 85.4	2.8^a	¹²³I(3321 ^b)	[30]
¹²⁴Te(d,2n)¹²⁴I	15→0	Te	95	20.4 ± 2.2	¹²⁶I(0.5)	[12]
	15→8	Te	91.7	18.9	¹²⁵I(0.35 ^b), ¹²⁶I(0.39 ^b), ¹³¹I(0.08 ^b)	[13]
	16→6	Te	96.7	23.7^a	--	[14]
	14→0	TeO₂	89.6	15	¹²³I(1.16), ¹²⁵I(1.41), ¹²⁶I(1.16), ¹³⁰I (7.87), ¹³¹I(0.31)	[15]
	14→10	Te	99.8	17.5^a	¹²⁵I(1.7)	[16]
^natSb(α,xn)¹²⁴I	22→13	Sb	Nat	1.02^a	¹²³I(892 ^b), ¹²⁵I(13 ^b), ¹²⁶I(0.16 ^b)	[31]
¹²¹Sb(α,n)¹²⁴I	22→13	Sb	99.45	2.11^a	¹²³I(891 ^b), ¹²⁵I(<0.2), ¹²⁶I(<0.2)	[31]
^natSb(³He,xn)¹²⁴I	35→13	Sb	Nat	0.95^a	¹²¹I(37700 ^b), ¹²³I(3877 ^b), ¹²⁵I(0.6), ¹²⁶I(0.6)	[32]

^a Based on experimental cross section data; ^b Percent calculated here from the ratio of the published saturation yield data.

Prior to examining the difference between the ¹²⁴I radioiodine purity of these two reactions, it is important to note that radioiodine contaminants may arise from one of two sources [22]. Firstly, as the natural composition of tellurium is given as ¹²⁰Te (0.09%), ¹²²Te (2.55%), ¹²³Te (0.89%), ¹²⁴Te (4.74%), ¹²⁵Te (7.07%), ¹²⁶Te (18.84%), ¹²⁸Te (31.74%), and ¹³⁰Te (34.08%) [23], the ¹²⁴Te target material must be highly enriched as the presence of other tellurium isotopes will permit reactions which give rise to radioiodine contaminants. This source of contaminants is not however the limiting concern when producing ¹²⁴I as target materials of higher enrichment may always be employed. Although enrichment levels greater than 99 percent are common (Table 1), the high cost of the enriched tellurium imposes the need for recycling the irradiated target material [13].

The second source of radioiodine contaminants arises from the fact that, despite 100 percent enrichment, competing reactions may occur during the ¹²⁴Te irradiation. For the energy range employed in the ¹²⁴Te(p,n)¹²⁴I and ¹²⁴Te(d,2n)¹²⁴I reactions, the primary competing reactions of concern are ¹²⁴Te(p,2n)¹²³I and ¹²⁴Te(d,n)¹²⁵I, respectively. Given the difference in half-lives for ¹²³I (t ½ = 13.2 hrs) and ¹²⁵I (t ½ = 59.4 days), a mixture containing ¹²³I and ¹²⁴I will present a greater ¹²⁴I purity over time. In contrast, a mixture of ¹²⁴I and ¹²⁵I will present a decrease in ¹²⁴I purity with time. It is for this reason that although the ¹²⁴Te(p,n)¹²⁴I may present with a lower ¹²⁴I radioiodine purity than ¹²⁴Te(d,2n)¹²⁴I at the end of the irradiation, the ¹²⁴Te(p,n)¹²⁴I reaction will give rise to a higher radioiodine purity following a period of decay [15].

As the probability for competing reactions to occur during the irradiation of a particular tellurium isotope depends upon the irradiation energy, it is common to strategically select the irradiation energy window to maximize the production of ¹²⁴I while minimizing the radioiodine impurities [14,16,24]. The selection of this energy window typically results in a trade-off between purity and yield. For example, although the ¹²³I contaminant arising from the ¹²⁴Te(p,2n)¹²³I reaction may be minimized by reducing the incident proton energy, a decrease in energy from 13 MeV to 11 MeV results in a near three-fold decrease in the ¹²⁴I yield [20]. In some cases, for example the ¹²⁶Te(p,3n)¹²⁴I reaction, if the entire proton energy were to be deposited in the ¹²⁶Te target, large ¹²⁵I and ¹²⁶I impurities from the competing ¹²⁶Te(p,2n)¹²⁵I and ¹²⁶Te(p,n)¹²⁶I reactions would result. To minimize these impurities, the exit energy is controlled by varying the thickness of the target material.

In examining the three proton induced reactions on enriched tellurium, the ¹²⁵Te(p,2n)¹²⁴I [24,25,26,27] and ¹²⁶Te(p,3n)¹²⁴I [28,29] reaction pathways offer 5–9 times higher ¹²⁴I yields than the ¹²⁴Te(p,n)¹²⁴I strategy [29]. The major shortcomings to these two reaction schemes are that, (i) higher proton energies are needed and, (ii) the level of long-lived radioiodine contaminants is increased. A search for alternative methods of producing ¹²⁴I has lead to investigations of the ¹²³Te(d,n)¹²⁴I [30], ^natSb(α,xn)¹²⁴I [13,31], ¹²¹Sb(α,n)¹²⁴I [31], and ^natSb(³He,xn)¹²⁴I [32] reactions. As a result of the low yields reported, these four reaction schemes are not ideal for clinical production of ¹²⁴I. Given the low yields observed for the antimony-based reactions, the remainder of the discussion on ¹²⁴I production and recovery is limited to tellurium-based target materials.

The number of reaction strategies available for the production ¹²⁴I at a particular facility is dictated by the irradiation energies and particles available. If multiple schemes are possible, the choice of which reaction strategy to employ requires a thorough evaluation of the desired ¹²⁴I yields and the tolerable level of radioiodine impurities at the time of administration. As noted by Scholten et al. [29], although ¹²⁴I of the highest radioiodine purity may be recommended for diagnostic applications, a higher impurity level may perhaps be more tolerable when harnessed for therapeutic purposes.

2.2. Thermal design and irradiation considerations

As the total ¹²⁴I activity produced is proportional to the current at which the target is irradiated, higher currents are always desired (particularly given the generally low yield of ¹²⁴I). Unfortunately, due to the large power dissipated into the target material (e.g. 300 W given 20 μA of 15 MeV protons) the maximum current at which a target may be irradiated is dictated by the thermal performance of the target material itself. Evidence of inadequate thermal performance during the irradiation is given by the presence of volatile ¹²⁴I and/or tellurium [33,34], or in some cases, significant melting of the expensive tellurium target material [35,36].

To maintain a superior thermal performance during high-current target irradiations, extensive cooling of the target material and support plate is essential. Commonly, this is achieved through water cooling on the back of the target support plate and helium cooling on the front surface of the tellurium target material [18,21,37,38]. Although 4 π water cooling has been employed [18,26,27], Qaim et al. [18,26] have noted appreciable losses of ¹²⁴I to the cooling water with this configuration. For the purpose of improving the target cooling efficiency, several studies have examined the use of finite-method based computer simulations to model the heat transport during the target irradiation [34,39,40,41].

The chemical and physical form of the tellurium has an impact on the thermal stability of the irradiated target. The most common target material employed for ¹²⁴I production is TeO₂ (m.p. 733 ºC). This material is attributed to having better thermal characteristics when compared to tellurium metal [33,37]. It is common to add 5–7% by mass Al₂O₃ to the TeO₂[18,20,21,37,42,43] for the purpose of (i) enhancing the binding of the TeO₂ to the target plate [18,37,43,44], (ii) giving the target material a glassy solid structure thus eliminating the need for a cover foil [37,44], and (iii) increasing the uniformity of the target material layer [44]. As investigated by Nye et al. [33], Al₂Te₃ appears to be a promising target material given its high melting point (m.p. 895 ºC), high tellurium mass fraction and its formation of a glassy-melt. McCarthy et al. [45], and Rowland et al. [46] have also investigated the use of Cu₂Te (m.p. 1132 ºC). For the purpose of improving the thermal performance of elemental tellurium targets, Sadeghi et al. [47] and Yanbawi et al. [48] have recently explored methods for optimizing tellurium electrodeposition techniques.

In addition to the tellurium target material, the support plate in which the target material is deposited must be considered. In selecting a support plate, Bosch et al. [49] discuss how its selection is a compromise between thermal conductivity, chemical resistance, adhesion of the tellurium target material and desire for low and short-lived, non-volatile, induced radioactivity at temperatures ranging from room temperature to the melting point of the target material. Although platinum generally serves this purpose (commonly with furrows scratched into the surface [21,37], or platinum gauze employed [18,49] to increase the adhesion with the target material), both Sheh et al. [37] and Glaser et al. [19] report a warping of the platinum support plate. While Sheh et al. [37] attribute this deformation to a misalignment of the proton beam, Glaser et al. [19] suggest that the warping occurs as a result of the differences in the thermal expansion coefficients between TeO₂ and platinum. As an alternative support plate, Alekseev et al. [50] suggest that tantalum offers a good compromise between thermal conductivity and strength. They claim however that it is impossible to form a strong elemental tellurium coating directly onto the tantalum. To overcome this challenge, they electroplate nickel onto the tantalum to act as an intermediate binding layer. Examples of other target plate support materials which have been employed for ¹²⁴I production include nickel electroplated copper [12,47], tungsten [45], platinum coated tungsten [46], silicon [45], platinum (90%) iridium (10 %) [15,51,52], and rhodium electroplated stainless steel [53].

In addition to target cooling and material selection, there are three more factors which are also commonly varied for the purpose of increasing the thermal performance of the irradiated target. First, as was discussed in the previous section, the target thickness is often reduced so that the entire beam energy is not deposited within the target itself. This reduction in thickness not only serves the purpose of limiting the competing reactions which may give rise to radioiodine impurities, it allows for some of the heat to be deposited into the target support plate. The reduction in thickness also offers the added benefit of reducing the material costs [24]. Second, the power density to the target is commonly reduced by slanting the irradiated target [20,21,27,37,51]. This incline increases both the area over which the heat is deposited and the effective target thickness. Finally, to achieve a more uniform heat distribution, and avoid potential “hot-spots”, it is common to defocus or wobble/sweep the beam across the target [14,18,21,38,42].

Although the thermal performance of a target is often considered to be the current-limiting factor, several novel studies have investigated methods for exploiting the ¹²⁴I volatility during irradiation for the purpose of performing on-line ¹²⁴I extraction. Examples of such studies include the Te(70)/Tl(30) eutectic (m.p. 224 ºC) investigated by Zyuzin et al. and Johnson et al. [54,55], the TeO₂-based target system (m.p. 733 ºC) explored by Stevenson et al. [53], and the tellurium metal-based system (m.p. 452 ºC) evaluated by Runz et al. [36].

2.3. Processing: Dry distillation of the ¹²⁴I

Of the two methods employed for separating ¹²⁴I from an irradiated tellurium target, dry distillation is commonly preferred over wet chemical processing as it is reasonably straightforward to perform and allows for recycling of the target without further handling [51]. As dry distillation requires a material with good melting and solidification properties, TeO₂ is most commonly employed since elemental tellurium has a tendency to “blow up” upon heating [49]. A conventional dry distillation setup entails the heating of an irradiated target under gas flow in a quartz tube. Given the increased vapor pressure of the iodine compared to the tellurium target material, the iodine is transported through the quartz tube and trapped downstream of the furnace. Although the following summary focuses on the dry distillation of TeO₂, successful dry distillation ofAl₂Te₃ [33] and Cu₂Te [45,46] have been reported.

For the purpose of maximizing the ¹²⁴I recovery while minimizing the loss of the expensive tellurium target material, a wide variation in the setup parameters is noted in the literature. While the distillation time is commonly kept relatively short (typically varied from 5–20 min [18,19,37,51]), the distillation temperatures reported in the literature show a wide variation 670 ºC [37]–820 ºC [25]. It should be noted that this temperature variation may perhaps be attributed, in part, to differences between the oven temperature set-point and the true target material temperature (a 40 ºC difference in these two values was noted by Sheh et al. [37]). As the tellurium loss has been related to increased distillation times and increased temperatures, both Qaim et al. [18] and Scholten et al. [29] recommend that a 15 min distillation at 750 ºC offers a good compromise between the tellurium loss and ¹²⁴I recovery. In contrast, Zweit et al. [28] report optimal distillation conditions of 770 ± 5 ºC for 20 min. To further reduce the heating time required for release of the ¹²⁴I, the use of an induction furnace, as opposed to the conventional tube oven has been proposed [45,46,56].

As noted by Glaser et al. [19] the tellurium detected in the final ¹²⁴I product vial increases as a target undergoes repeated irradiation/processing cycles. To minimize the metallic tellurium from reaching the ¹²⁴I trap, the use of an Al₂O₃/quartz wool filter has been reported [19,57]. Qaim et al. [18] place a strong emphasis on the need for annealing the TeO₂/Al₂O₃ target mixture at 450 ºC for the purpose of converting small amounts of TeO₃ to TeO₂. If this step is not performed, they report an increase in tellurium loss during the distillation process. Although air [15,18,21,29], argon [43], helium [53] and oxygen [19,27,28,37,38] have all been employed as carrier gases during the ¹²⁴I dry distillation process, Glaser et al. [19] note the preference of an oxygen atmosphere for the purpose of regenerating the target as reduced tellurium has a higher volatility than TeO₂. Carrier gas flow rates reported in the literature typically range from 15–40 mL/min [20,21,25,43,51], however, rates as low as 5 mL/min [37] and as high as 80 mL/min [27] have been reported. Although there is limited discussion in the literature as to flow rate optimization, Zweit et al. [28] report an optimal oxygen flow rate of 24 mL/min.

The trap employed for collecting the ¹²⁴I typically takes one of two forms. Firstly, the trap may be a solution of NaOH. Typical NaOH volumes range from 100–1000 μL [18,21,38], while typical concentrations range from 0.001–0.1 M [21,25,38]. The second trap design involves the use of a capillary tube. Reported tube materials include stainless steel [15,51], Pyrex [37] and quartz [20,43]. To increase the trapping efficiency, the capillary tubes may be primed with NaOH [37,51]. Loading of the capillary tube with platinum wire has also been reported for the purpose of increasing the surface area [20]. The ¹²⁴I which has settled onto the surface of the capillary is recovered by washing the capillary with a weak buffer solution [20,37]. To enhance the ¹²⁴I trapping, the NaOH or capillary traps may be cooled [20,21,37]. To prevent premature precipitation of the distilled iodine in the region between the furnace and the trap, this region is commonly heated using a stream of hot air [18,29] or a heat wire/ribbon [19,20,27,49]. A temperature of 200 ºC is recommended in this region for ensuring efficient ¹²⁴I transport [19,49]. For the purpose of preventing the release of any un-trapped volatile ¹²⁴I, a second NaOH trap [18,27,29], or a charcoal filter [19,49] is often placed downstream of the primary ¹²⁴I trap.

2.4. PET imaging of ¹²⁴I

PET relies on the detection of the two back-to-back 511 keV photons in coincidence. These two photons arise from positron annihilation following the positron (β⁺) decay of the radioisotope on the labelled pharmaceutical. As these two annihilation photons are emitted in opposite directions (nearly 180º), the annihilation event is taken to have occurred along the path joining the two detectors (referred to as the line of response (LOR)). It is the acquisition of many such LORs which allows for localization of the radiopharmaceutical uptake within a patient. PET imaging of ¹²⁴I introduces several challenges over the imaging of traditional PET isotopes (i.e.,¹⁸F and ¹¹C).

Firstly, for the traditional PET isotopes, β⁺ decay occurs greater than 96 percent of the time. For ¹²⁴I however, β⁺ decay occurs only 23 percent of the time with the positrons having higher energies when compared with the traditional PET isotopes. This low branching ratio results in the need for longer imaging times to achieve similar counting statistics assuming similar starting activities [58].

Next, the traditional PET isotopes always decay to the ground state of the daughter nucleus. For ¹²⁴I however, the decay scheme is significantly more complex. Approximately 65 percent of the time, the decay of ¹²⁴I populates an excited state of ¹²⁴Te. The consequence of decaying to an excited state (as opposed to the ground state) is that a cascade of high energy photons follows the ¹²⁴I decay as the ¹²⁴Te nucleus de-excites. As there is no angular correlation between the annihilation photons and the cascade photons [59,60], the detection of a cascade photon and an annihilation photon within the timing window of the PET scanner will give rise to a falsely identified LOR. If uncorrected, these prompt gamma coincidences (PGC) will lead to spurious activity in the final reconstructed image [59]. To account for the PGCs in non-conventional PET radionuclides, it is common to encompass corrections within the image reconstruction process [59,61,62,63] and/or optimize the image acquisition parameters to limit the detection of the cascade photons [60,64,65].

It should also be noted that as a result of these additional high energy cascade photons, the high energy positrons associated with ¹²⁴I decay, and the long half-life of ¹²⁴I, the radiation burden associated with ¹²⁴I is increased when compared with the traditional PET isotopes. This results in lower injected activities of ¹²⁴I-labelled radiopharmaceuticals, and in turn, the need for increased imaging times to achieve the desired counting statistics.

Finally, as a result of the increased positron energy when compared to the positrons arising from the decay of the traditional PET isotopes, the positrons will travel a greater distance prior to annihilation. Although this increased distance results in a degradation of the image point spread function [66], Liu and Laforest [67] have recently reported a method for accurately determining the activity concentration in small lesions for PET imaging of several long range position emitters.

3. Basic Principles of Radiochemistry with Radioiodine Isotopes

Radioiodination chemistry generally employs the same chemistry used in organic synthetic chemistry involving non-radioactive iodine. However, the synthetic methods involving radioiodine nuclides must be adapted to special reaction conditions considering the half-life of the radionuclide and the use of small-scale concentrations. In recent decades, methods of radioiodination have been reviewed extensively in the literature with emphasis placed on labeling methods, mechanistic aspects, and applications of radioiodinated compounds [68,69].

Radiochemistry involving radioiodine nuclides can principally be subdivided into nucleophilic and electrophilic substitution reactions as the most general synthesis routes. These two reaction schemes are discussed in this review. A special discussion is also included on the radioiodine labeling of macromolecules such as peptides, proteins and antibodies.

The ease of oxidizing iodide into an electrophilic form of iodine makes electrophilic labeling the most frequently and most popular employed radioiodination method. The advantage of the easy oxidation of iodide in comparison with other radiohalogens (except astatine) and the subsequent straightforward electrophilic labeling chemistry is somewhat compromised by the lower stability of the carbon-iodine bond. The low stability of the carbon-iodine bond may result in substantial radiodeiodination in vivo, leading to the formation of radioiodide and its subsequent rapid accumulation in the thyroid and stomach. Aromatic carbon-iodine bonds are more stable than aliphatic carbon-iodine bonds. As a consequence, compounds containing an aromatic or vinylic carbon-iodine bond are more often prepared to confer as high metabolic stability towards radiodeiodination in vivo as possible.

3.1. Nucleophilic substitution reactions

Halogen exchange reactions are the most common method for the introduction of radioiodine into organic molecules. The nucleophilic exchange reactions can occur in aliphatic and aromatic compounds according to the nature of the leaving group. Compared to nucleophilic substitutions with aliphatic compounds, nucleophilic substitution reactions proceed slowly on aromatic compounds. Moreover, the aromatic substrate must be activated by electron-withdrawing groups. To accelerate the exchange reactions in aromatic compounds, various metal-assisted reactions proved to be quite successful for nucleophilic radioiodinations of arenes. Prominent examples include the use of ammonium salts or copper(I)- and copper(II)-assisted radioiodinations. Other methods involve treatment of aromatic diazonium salts or decomposition of triazenes in the presence of protic solvents or Lewis acids with sodium radioiodide.

3.2. Electrophilic substitution reactions

Electrophilic radioiodination reactions are the preferred method for radioiodinations of aromatic compounds. The method relies on the ease with which radioiodide can be oxidized in situ to a positively charged iodine (I⁺) species by means of various mild oxidizing agents. Commonly employed oxidizing agents include iodine monohalides like ICl, N-chloroamides like chloramine T, peracids like peracetic acid, N-halosuccinimides like N-chlorosuccinimide, and other oxidants like metal ions (e.g. Tl³⁺, Ce⁴⁺), iodate and enzymes (e.g. lactoperoxidase).

Electrophilic radioiodinations on an aromatic system can be performed directly (radioiodo-deprotonation) or by means of various demetallation techniques. Radioiodo-demetallation reactions require organometallic compounds as precursors. Radio-demetallation reactions with electropositive radioiodine involving organometallic compounds like organoboranes, group IV metal-containing compounds (Si, Ge, Sn), and organomercury and organothallium compounds usually proceed in high radiochemical yield in a highly regioselective manner.

Among the known demetallation reactions, destannylation reactions are the most favoured method for electrophilic radioiodinations. Radioiodo-destannylation reactions proceed well under fairly mild reaction conditions affording the radioiodinated product in high radiochemical yields and high regioselectivity even by using only very small quantities of organotin precursors (<50 μg).

3.3. Radioiodination of peptides and proteins

Various methods for the radioiodination of proteins and antibodies under mild reaction conditions compatible with the structural and functional integrity of proteins have been developed. Methods include the direct labeling of proteins through radioiodination of tyrosine residues with electropositive radioiodine. Chloramine T, Iodogen^®, and various oxidative enzymes are useful oxidizing agents for the mild in situ oxidation of radioiodide for direct protein labeling.

Another approach deals with the application of radioiodinated bifunctional labeling precursors, also referred to as prosthetic groups. Here the peptide or protein is reacted with an iodinated molecule which has been activated for conjugation with functional groups of the peptide or protein. Commonly used functional groups of peptides or proteins for conjugation with prosthetic groups are amine and sulfhydryl groups as typically found in lysine and cysteine residues.

4. Examples for ¹²⁴I-labeled Compounds

The following part of the review summarizes the synthesis and application of various ¹²⁴I-labeled compounds as molecular imaging probes for PET. The survey is organized based on the employed synthesis route for the preparation of the ¹²⁴I-labed compounds.

4.1. ¹²⁴I-labeled compounds prepared via nucleophilic exchange reactions

4.1.1. meta-[¹²⁴I]Iodobenzylguanidine ([¹²⁴I]MIBG)

m-Iodobenzylguanidine (MIBG) is used in diagnosis (labeled with ¹²³I or ¹²⁴I) and therapy (labeled with ¹³¹I) of neuroblastoma and pheochromacytoma. A recent study describes the use of ¹²⁴I-labeled MIBG for imaging norepinephrine transporter (NET) function [70]. The synthesis of [¹²⁴I]MIBG was performed according to a nucleophilic halogen exchange reaction with [¹²⁴I]NaI in the presence of Cu(I) at elevated temperatures. Copper(I) was generated in situ through reduction of Cu(II)-sulfate with tin(II). The overall radiochemical yield was greater than 80%. The reaction is given in Scheme 1.

Scheme 1. [¹²⁴I]MIBG synthesis via Cu(I)-assisted nucleophilic exchange reaction.

4.1.2. 1-α-D-(5-deoxy-5-[¹²⁴I]iodo-arabinofuranosyl)-2-nitroimidazole ([¹²⁴I]IAZA)

The hypoxia imaging agent [¹²⁴I]IAZA was used in a comparative study with two other 2-nitro-imidazole derivatives ([¹⁸F]FMISO and [¹⁸F]FAZA) for the visualization of tumor hypoxia in A431 bearing mice by means of PET [71]. [¹²⁴I]IAZA was prepared by an isotopic exchange reaction with [¹²⁴I]NaI (Scheme 2).

Scheme 2. Synthesis of hypoxia imaging agent [¹²⁴I]IAZA.

4.1.3. [¹²⁴I]Iodo-azomycin-galactopyranoside ([¹²⁴I]IAZG)

[¹²⁴I]Iodo-azomycin-galactopyranoside ([¹²⁴I]IAZG) as another ¹²⁴I-labeled hypoxia imaging agent was reported by Zanzonico et al. [72]. [¹²⁴I]IAZG was prepared based on a nucleophilic isotope exchange reaction according to a literature procedure involving iodine-125 and iodine-123 (Scheme 3) [73,74,75].

Scheme 3. Synthesis of hypoxia imaging agent [¹²⁴I]IAZG.

Small animal PET studies with [¹²⁴I]IAZG and [¹⁸F]FMISO, another hypoxia PET tracer, were performed in MCa breast tumors and FSaII fibrosarcomas implanted in mice. [¹²⁴I]IAZG showed high uptake in large tumors. PET imaging with [¹²⁴I]IAZG was optimal after 24 h post injection (p.i.), when the whole body background activity had dissipated. As a result, [¹²⁴I]IAZG showed a tumor uptake of 17% at 48 h p.i., whereas tumor uptake for [¹⁸F]FMISO was 5–10% at 3–6 h p.i..

Comparable results were observed for Morris hepatoma McA-R-7777 tumors as reported by Riedl et al. [74,75]. Substantial uptake of radioactivity in the thyroid accounting for 30% of the total-body activity at 48 h p.i. is indicative of radiodeiodination of [¹²⁴I]IAZG in vivo. The presented data indicate the potential of [¹²⁴I]IAZG for hypoxia imaging.

4.1.4. 1-(2-Deoxy--β-D-ribofuranosyl)-2,4-difluoro-5-[¹²⁴I]iodobenzene ([¹²⁴I]dRFIB)

1-(2-Deoxy-β-D-ribofuranosyl)-2,4-difluoro-5-[¹²⁴I]iodobenzene ([¹²⁴I]dRFIB) for imaging cell proliferation was introduced by Stahlschmidt et al. [76]. The radiotracer was synthesised in five steps following the literature-reported method and radioiodination was accomplished via nucleophilic isotope exchange reaction in the presence of copper sulphate and ammonium sulphate (Scheme 4).

Scheme 4. Synthesis of [¹²⁴I]dRFIB.

The precursor was mixed with a solution containing copper and ammonium sulphate in water. The required amount of [¹²⁴I]NaI was added in NaOH. The vial was sealed, and a venting needle attached to an activated carbon cartridge was used. The solvent was evaporated in a stream of dry nitrogen and the residue was heated. The product was purified and isolated by means of a C₁₈ cartridge and HPLC. The reaction was optimized through screening different temperatures and precursor amounts. A radiochemical yield of 2.4% was obtained at 60 ºC, which was increased to 10% at 80 ºC and 76% at 100 ºC. Optimized reaction conditions provided [¹²⁴I]dRFIB in radiochemical yields of up to 85% within one hour. No data on the radiopharmacological evaluation of [¹²⁴I]dRFIB are reported.

4.2. ¹²⁴I-labeled compounds prepared via electrophilic substitution reactions

4.2.1. Direct electrophilic substitution on activated aromatic systems

4.2.1.1. 5-[¹²⁴I]Iodo-2′-deoxyuridine ([¹²⁴I]IUdR)

Radiosynthesis of 5-[¹²⁴I]Iiodo-2′-deoxyuridine ([¹²⁴I]IUdR) for functional imaging of cell proliferation by means of PET was investigated by Guenther et al. [77]. Radiolabeling of [¹²⁴I]IUdR was performed via direct electrophilic substitution method using Iodogen^® as the oxidising agent (Scheme 5).

Scheme 5. Synthesis of 5-[¹²⁴I]iodo-2’-deoxyuridine ([¹²⁴I]IUdR).

2'-Deoxyuridine as the labeling precursor was dissolved in 0.2 M phosphate buffer (250 µL) and added to an Iodogen^®-coated Reacti-vial. After the addition of 185 MBq of [¹²⁴I]NaI, the reaction was performed at 65 ºC for 15 min. After cooling to room temperature the product was separated via solid phase extraction on a Sep-Pak C-18 cartridge. The cartridge was eluted with ethanol which was evaporated under a stream of nitrogen. The residue was re-dissolved in saline and filtered through a 0.22 µm sterile filter. The labeling yield was 45–65% and the purity was greater 93% [77]. [¹²⁴I]IUdR showed rapid radiodeiodination in vivo resulting in high accumulation of activity in the thyroid. After 24 h p.i. brain tumor imaging with [¹²⁴I]IUdR was feasible [78].

4.2.1.2. ¹²⁴I-labeled hypericin

Recently, Kim et al. described the synthesis of ¹²³I- and ¹²⁴I-labeled hypericin derivatives [79]. Hypericin, a natural polycyclic aromatic dianthraquinon, was used in treatment of depression and showed antiretroviral activity against several viruses including human immunodeficiency virus (HIV). Additionally, an elevated activity against protein kinase C (PK-C) was found in malignant gliomas. Kim et al. investigated the possibility of using iodine labeled hypericin derivatives for imaging malignant gliomas with PET and SPECT [79].

Scheme 6. Synthesis of ¹²⁴I-labeled hypericin.

Hypericin as a labeling precursor was synthesised in 65% yield. Conversion of hypercin with sodium iodide in presence of peracetic acid afforded the non-radioactive reference compound. Iodination of hypercin gave various products which could be separated by semi-preparative HPLC.

Radiosynthesis was performed in the presence of phosphoric acid and peracetic acid as an oxidising agent according to Bormans et al., [21]. [¹²⁴I]NaI in NaOH was slowly added to a 0.5 mg/mL solution of hypericin in EtOH containing 0.5 M H₃PO₄ (25 µL) and 0.2 M peracetic acid (50 µL) (Scheme 6). After incubation at room temperature for 30 min, the reaction mixture was purified by HPLC. No information on radiochemical yield, purity or specific activity was given. Cellular uptake studies were performed using ¹²⁴I-labeled hypericin. ¹²⁴I-labeled hypericin provided good quality small animal PET images using PK-C overexpressing malignant glioma mouse xenografts.

4.2.1.3. 2'-Fluoro-2'-deoxy-1-β-D-arabinofuranosyl-5-[¹²⁴I]iodouracil ([¹²⁴I]FIAU)

An ¹²⁴I-labeled uracil derivative [2'-fluoro-2'-deoxy-1-β-D-arabinofuranosyl-5-iodouracil (FIAU)] has been reported as a PET radiotracer for non-invasive imaging of herpes virus thymidine kinase (HSV1-tk) gene transfer and expression for monitoring clinical gene therapy [80].

Scheme 7. Synthesis of [¹²⁴I]FIAU.

The first synthesis of [¹²⁴I]FIAU was published by Tjuvajev et al. in 1996 [80]. [¹²⁴I]FIAU was prepared by hydrogen-to-iodine exchange using 2'-fluoro-2'-deoxy-1-β-D-arabinofuranosyl uracil (FAU) as a labeling precursor and Iodogen^® as an oxidising agent.

An improved synthesis of [¹²⁴I]FIAU was described by Doubrovin et al. [81]. This no-carrier-added synthesis of [¹²⁴I]FIAU is based on the reaction of the stannylated labeling precursor 2'-fluoro-2'-deoxy-1-β-D-arabinofuranosyl-5-(tri-n-butyltin)-uracil (FTBSnAU) with [¹²⁴I]NaI in the presence of acetic acid and 30% hydrogen peroxide as an oxidising agent. After quenching the reaction by the addition of sodium metabisulfite, [¹²⁴I]FIAU was isolated by solid phase extraction on a C-18 Sep-Pak cartridge. After elution with methanol the product was reconstituted in sterile and pyrogen-free physiological saline (with 5% ethanol added) and passed through a sterile filter. The radiochemical purity was determined to be greater than 97%. The specific activity was not determined. Brust et al., published a slightly modified method based on 5-trimethylstannyl-1-(2-deoxy-2-fluoro-D-arabino-furanosyl) uracil (FTAU) as the labeling precursor. The obtained radiochemical yield was 70%, and the radiochemical purity exceeded 98%. [82]

Small animal PET-studies showed clear accumulation of [¹²⁴I]FIAU in HSV1-tk expressing tumors. In 1998 Tjuvajev et al. showed that a retroviral HSV1-tk gene transfer results in an expression level that can be measured by PET. PET imaging at later time points (24 h) is advantageous [83]. Compared with the ¹⁸F-labeled PET tracer 9-[(3-[¹⁸F]fluoro-1-hydroxy-2-propoxy)methyl]guanidine ([¹⁸F]FHPG), [¹²⁴I]FIAU showed significantly higher accumulation in HSV1-tk expressing cells [82].

4.2.2. Electrophilic radioiodo-destannylation reactions

4.2.2.1. ¹²⁴I-labeled m-iodophenylpyrrolomorphinan (m-[¹²⁴I]IPPM)

Reports of pharmacological studies on delta-opioid receptors to assess functional receptor expression and advance opioid receptor targeting drugs suggest the use of ¹²⁴I-labeled compound m-iodophenylpyrrolomorphinan (m-[¹²⁴I]IPPM) as a radiotracer for molecular imaging with PET [84].

The synthesis of morphine compounds as reference compound and precursors for radiolabeling with ¹²⁴I is depicted in Scheme 8.

Scheme 8. Synthesis of the reference compound m-IPPM and m-[¹²⁴I]IPPM: a) benzene, 0 ºC; b) phenylhydroazonium chloride, 0 ºC, pyridine, room temperature; c) Zn, HOAc/NaOAc, 60 ºC, then reflux; d) Sn₂Me₆, PdCl₂(PPh₃)₂; e) [¹²⁴I]NaI, Iodogen^® beads.

The reference substance m-IPPM was converted into the stannylated labeling precursor A by a Pd-mediated reaction with hexamethyldistannane. The radiolabeling was performed via an electrophilic iodo-destannylation reaction using [¹²⁴I]NaI in 5% acetic acid in methanol. Iodogen^® beads were used as an oxidising agent to afford m-[¹²⁴I]IPPM. The overall radiochemical yield was 24.5 ± 1.9% (n = 6), and the product was obtained in >98% radiochemical purity at a specific activity of 92.5 ± 44.4 MBq/µmol.

4.2.2.2. [4-(3-[¹²⁴I]iodoanilino)-quinazolin-6-yl]amide-(3-morpholino-4-ylpropyl)amide (mor-pholino-[¹²⁴I]IPQA)

Molecular imaging of EGFR kinase activity in tumors has been performed with (E)-but-2-enedioic acid [4-(3-[¹²⁴I]iodoanilino)-quinazolin-6-yl]amide-(3-morpholino-4-ylpropyl)amide (morpholino-[¹²⁴I]IPQA) [85]. Morpholino-[¹²⁴I]IPQA should allow non-invasive and repetitive imaging of EGFR signalling inhibitors before and during therapy with EGFR inhibitors. Several carbon-11 and fluorine-18 labeled radiotracers for imaging EGFR been developed. However, the short half-lives of these tracers have limited their use in PET imaging [86,87]. On the other hand, the longer half-life of ¹²⁴I should allow imaging at later time points to provide a higher signal-to-noise ratio. Scheme 9 displays the synthesis of the reference and precursor compounds, and the radiolabeling with ¹²⁴I.

Scheme 9. Synthesis of the reference compound morpholino-IPQA, precursor A and radiolabeling: a) EDC, HCl, DMAP, DMF b) EDC, HCl, HOBt, CH₂Cl₂ c) [¹²⁴I]NaI, NaOH, MeOH, H₂O₂/HOAc (1:3), 1 min vortex, 2 min room temperature.

As outlined in Scheme 9, radiolabeling was achieved through electrophilic aromatic iodination using stannylated compound A and [¹²⁴I]NaI in methanol. Hydrogen peroxide/acetic acid was used as oxidising agent. The reaction mixture was vortexed for one minute and then allowed to stand for two minutes. Afterwards aqueous saturated sodium metabisulfate (0.1 mL) was added to quench the reaction. The product was purified by gradient elution from a C-18 Sep-Pak cartridge. Morpholino-[¹²⁴I]IPQA derivative was obtained in 14.4% radiochemical yield. The radiochemical purity was 85.9%. Preliminary in vitro studies using human epidermoid carcinoma (A431), human glioma (U87MG), and human chronic myeloid leukemia (K562) cell lines were conducted with ¹³¹I-labeled morpholino-IPQA. Small animal PET studies with morpholino-[¹²⁴I]IPQA in rats revealed a significant difference in radiotracer accumulation in EGFR positive A431 tumors and EGFR negative K562 xenografts. In A431 tumor xenografts, tumor-to-muscle and tumor-to-blood concentration ratios of 4.5 and 3.7 were achieved 60 min p.i.. In contrast, tumor-to-muscle and tumor-to-blood concentration ratios were 1.25 and 1.04, respectively, in K562 tumor xenografts [85].

4.2.2.3. ¹²⁴I-labeled 6-anilino-quinazoline derivatives as EGFR inhibitors

Shaul et al. also described different ¹²⁴I-labeled radiotracers with irreversible binding to EGFR [88]. The compounds contain a quinazoline backbone. α-Methoxyacetamide [¹²⁴I]ML07 was found to be less potent while α-chloroacetamide [¹²⁴I]ML08 and 4-dimethylaminobut-2-enoic amide derivative [¹²⁴I]ML06 possess high potency. The radiolabeling of all compounds is based on iodo-destannylation reaction, as depicted in Scheme 10.

Scheme 10. Synthesis of ¹²⁴I-labeled EGFR-inhibitors: a) Sn₂Bu₆, Pd(PPh₃)₄, THF; b) [¹²⁴I]NaI, NaOH, HCl, Chloramin T; c) BrCH₂CHCHCOCl; d) Me₂NH; e) ClCH₂COCl; f) MeOCH₂COCl.

Labeling precursor A was treated with [¹²⁴I]NaI in ethanol containing 0.1 N HCl with 1 mg/mL of Chloramine T as the oxidizing agent at room temperature to afford 6-amino-4-[(3-[¹²⁴I]-iodophenyl)amino]quinazoline ([¹²⁴I]11) in 50% radiochemical yield after 15 minutes. The product was purified by solid phase extraction. Compounds [¹²⁴I]ML07 and [¹²⁴I]ML08 were prepared by adding methoxy- or chloroacetylchloride in dry THF to the eluate containing [¹²⁴I]11 at 0 ºC. [¹²⁴I]ML07 was obtained in 28% at a specific activity >222.0 MBq/µmol. [¹²⁴I]ML08 was isolated in 36% at comparable specific activity. Synthesis of [¹²⁴I]ML06 includes three-steps starting from stannyl precursor A to provide [¹²⁴I]ML06 in 45% radiochemical yield [88].

4.2.2.4. Synthesis of ¹²⁴I-labeled purpurinimide derivatives

Three ¹²⁴I-labeled purpurinimides containing a iodobenzyl substituent have been synthesized and studied as tumor imaging agents with PET [89]. The compounds are porphyrine-based derivatives from methylpheophorbide-a isolated from Spirulina pacifica. The labeling precursors were prepared by Pd-mediated conversion of the corresponding iodine compounds into trimethyl-stannyl compounds. Radiolabeling was achieved through radioiodo-destannylation in the presence of [¹²⁴I]NaI and Iodogen^® beads as an oxidising agent. The reaction took 15 min at room temperature. The final products were purified using HPLC. The radiochemical yield was about 40%, and the specific activity was >37.0 GBq/µmol. The synthesis is given in Scheme 11.

Scheme 11. Synthesis of the ¹²⁴I-labeled purpurinimide derivatives [¹²⁴I]12, [¹²⁴I]14 and [¹²⁴I]16: a) (i) n-hexyl amine (ii) HBr/AcOH (iii) 3-Iodobenzyl alcohol; b) (i) 3-iodobenzyl amine (ii) HBr/AcOH (iii) R-OH; c) Sn₂Me₆, PdCl₂(PPh₃)₂; d) Iodogen^®, [¹²⁴I]NaI.

Biological studies using PET were performed in C3H mice bearing RIF tumors. Compounds [¹²⁴I]12 and [¹²⁴I]14 showed exceptionally high liver (32-fold and 8-fold, respectively) and spleen uptake (85-fold and 3-fold, respectively) at 24 h p.i. preventing visualization of the tumor. Compound [¹²⁴I]16 bearing a methyl ester instead of a hexyl ester showed reduced uptake in spleen and liver leading to visible tumor uptake after 96 h p.i..

4.2.2.5. Synthesis of ¹²⁴I-labeled 2-(4-iodophenylamino) pyrido[2,3-d]pyrimidin-7-one

Pyrido[2,3-d]pyrimidin-7-ones are potent tyrosine kinase inhibitors. A ¹²⁴I-labeled derivative (2-(4-[¹²⁴I]iodophenylamino) pyrido[2,3-d]pyrimidin-7-one ([¹²⁴I]18) was prepared as a radiotracer for imaging Abl kinase [90]. 4-Trimethylstannyl- and 4-tri-N-butylstannyl-pyridopyrimidinone were prepared as labelling precursors for subsequent radioiodo-destannylation with [¹²⁴I]NaI in the presence of 30% H₂O₂/HOAc (1:3) as an oxidizing agent. The product was obtained in 79–86% radiochemical yield with a high radiochemical purity of 99% within 30 min. The synthesis is summarized in Scheme 12.

Scheme 12. Synthesis of [¹²⁴I]18: a) Sn₂R₆, Pd(PPh₃)₄, microwave; b) [¹²⁴I]NaI, 30% H₂O₂:HOAc (1:3), 10 min, rt.

Radiopharmacological evaluation was reported for the corresponding ¹³¹I-labeled compound. Cell uptake studies in K562 cells revealed a growth inhibition (IC₅₀) value of 2.0 nM and a preferential accumulation in K562 cells compared with the control A431 cells.

4.2.2.6. Synthesis of n-(morpholin-4-yl)-1-(2,4-dichlorophenyl)-5-(4-[¹²⁴I]iodophenyl)-4-methyl-1h-pyrazole-3-carboxamide ([¹²⁴I]AM281)

Studies on central cannabinoid CB₁ receptors in schizophrenic patients led to the development of ¹²⁴I-labeled imaging probe [¹²⁴I]AM281 (Figure 1) [91]. ¹²⁴I-labeled AM281 was prepared according to a radioiodo-destannylation reaction starting from the corresponding tributyl-stannyl precursor with Chloramine T as an oxidising agent. [¹²⁴I]AM281 was purified via HPLC. 200 MBq [¹²⁴I]NaI was converted into 50 MBq of [¹²⁴I]AM281 for in vivo imaging. The PET study revealed an asymmetric CB₁ receptor binding in basal ganglia. The improved spatial resolution of [¹²⁴I]AM281 as PET radiotracer when compared with [¹²³I]AM281 as SPECT radiotracer is compromised by the longer half-life of iodine-124 leading to elevated radiation exposure limiting the amount of applicable activity [91].

Figure 1. Central cannabinoid CB₁ receptor ligand[¹²⁴I]AM281.

4.2.2.7. Synthesis of ¹²⁴I-labeled CDK4/6 inhibitors

Two ¹²⁴I-labeled cyclin-dependent kinase 4/6 inhibitors were developed to study the role of Cdk4/6 during cell proliferation in tumor cells [92]. 80% of human tumors show a deregulation of the cell cycle relevant Cdk4-cyclin D1/retinoblastoma (pRb)/E2F signal cascade resulting in uncontrolled tumor growth. Radiolabeled Cdk4 inhibitors have been suggested as promising molecular probes for imaging tumor cell proliferation. Based on selective Cdk4/6 inhibitors reported in the literature, two compounds were selected for radiolabeling via radioiodo-destannylation with iodine-124 [93,94]. The synthesis is given in Scheme 12.

Scheme 12. Radiolabeling of the Cdk4/6 inhibitors: a) [¹²⁴I]NaI, Iodogen^®, 5% HOAc in MeOH, DMSO, room temperature, 10 min; b) TFA.

C-6 Trimethylstannyl-substituted compounds were used as labeling precursors. Regioselective incorporation of I-124 into the C-6 position of pyrido[2,3-d]-pyrimidine compounds was accomplished with [¹²⁴I]NaI in the presence of mild oxidizing agents such as immobilised Chloramine-T (Iodobeads^®) or Iodogen^® followed by removal of the Boc protecting group to afford the desired radiolabeled compounds [¹²⁴I]CKIA and [¹²⁴I]CKIB. The optimisation was performed with trimethylstannyl-precursor (X = CH) and 2-3 MBq of [¹²⁴I]NaI (3–4 µL of [¹²⁴I]NaI in 0.25 M NaOH) at room temperature. The results clearly demonstrate that using 100–200 µg of labeling precursor (150 µL 1:3 mixture of DMSO and 5% acetic acid in methanol) and 1 Iodobead® affords 90% of radiolabelled compound Boc-[124]CKIA after 10 min with no side products. In a larger scale radiosynthesis (up to 275 MBq of [¹²⁴I]NaI) the use of iodobeads as the oxidising agent caused unexpected problems as most of the radioactivity was irreversibly attached to the iodobeads. When using Iodogen^®-coated tubes no undesired loss of activity was observed. Deprotection was performed with trifluoroacetic acid (TFA) at 50 ºC in 20 min to give the desired compound [¹²⁴I]CKIA in radiochemical yields of 45–65% The product was purified using semi-preparative HPLC column in combination with SPE on a Waters Sep-Pak-tC-18 cartridge. After HPLC the product was loaded onto the cartridge, washed with water and finally eluted with 1 ml ethanol to afford compound [¹²⁴I]CKIA with a radiochemical yield of 33.6%. Optimised reaction conditions were also applied to the synthesis of compound [¹²⁴I]CKIB, which was prepared with a radiochemical yield of 28%. Both compounds could be synthesised in high radiochemical purity (>95%) with a specific activites suitable for radiopharmaceutical investigations (35 GBq/µmol for [¹²⁴I]CKIA and 25 GBq/µmol for [¹²⁴I]CKIB). The log D (pH 7.4) values for compounds [¹²⁴I]CKIA and [¹²⁴I]CKIB were 2.77 ± 0.13 and 1.99 ± 0.03, respectively [92]. Graf et al., showed that the reference substances, when applied in nM-µM-scale were able to induce cell cycle arrest in G₁-Phase in HT-29 and FaDu cell lines [95] after 24 h. Also a high in vitro radiotracer cell uptake in HT-29 and FaDu tumor cells (approximately 750–850 %ID/mg protein [¹²⁴I]CKIA and 900–1,000 %ID/mg protein [¹²⁴I]CKIB (means) after 1 h) at 37 ºC was measured. Initial small animal PET imaging was performed in FaDu xenograft bearing mice revealing a predominantly hepatobiliary elimination, with no specific radioactivity accumulation in other organs and tissues, including the tumour. Biodistribution profile and ex vivo autoradiography-studies confirmed a clearance of the activity from most organs and tissues within 60 min after radiotracer administration, except for thyroid. The observed increase of radioactivity concentration in the thyroid is indicative of in vivo radio-deiodination and accumulation of free [¹²⁴I]iodide in the thyroid over time [92,95].

4.3. Radioiodination of peptides and proteins

4.3.1. Direct labeling of peptides and proteins with ¹²⁴I

Methods for radioiodination of peptides and proteins should be mild and rapid while providing high radiochemical yields.

¹²⁴I-labeled human insulin was prepared by Glaser et al. in 2001 by direct electrophilic iodination at the A₁₄-tyrosine residue [96]. Radioiodinated insulin labelled at A₁₄-tyrosine residue is known to retain receptor binding properties and biological activity as the native hormone.

Different oxidising agents, such as Iodogen^®, Chloramine-T, N-bromosuccinimide, and lactoperoxidase-hydrogen peroxide were investigated for direct radiolabeling of insulin with iodine-124 affording comparable radiochemical yields of about 33%.

Radiolabeling was performed in sodium phosphate buffer (pH 7.6) within 30 seconds. The specific radioactivity after single HPLC was 12.5 GBq/µmol and 25.8 GBq/µmol after tandem-HPLC. PET and biodistribution studies using ¹²⁵I- and ¹²⁴I-labeled insulin in rats showed uptake in both the myocardium and the liver. This uptake could be blocked with unlabeled insulin. Studies on the in vivo stability of radiolabeled insulin demonstrated rapid metabolism [96,97].

The long physical half-life of iodine-124 (t_1/2 = 4.2 d) is particularly well suited for labelling large molecules like antibodies. The relatively long half-life allows PET imaging at late time points (>24 h) ensuring sufficient accumulation of the radiolabeled antibody in the target tissue (e.g. tumor). Various ¹²⁴I-labeled antibodies have been used for molecular imaging and therapy breast cancer, colorectal cancer, ovarian cancer and neuroblastoma.

The radiolabeling was accomplished via direct radioiodination at tyrosyl and, to a lesser extent, histidyl residues of the antibody and protein using different oxidizing agents such as Iodogen^®, Chloramin T (CAT) and N-bromosuccinimide (NBS) in buffer at pH below 8.

Table 2 summarizes ¹²⁴I-labeled antibodies and proteins which have been prepared via direct electrophilic radioiodination.

Table 2. Direct labeling of proteins and antibodies with ¹²⁴I.

**Table 2.** Direct labeling of proteins and antibodies with ¹²⁴I.
Method	Imaging target	Antibody	Results	Reference
Iodogen^®	HER2	Anti-HER2	RCY: 13.8–18.8%;	[98]
	HER2	Anti-HER2	A_S: 33-102 MBq/mg,
	positive tumours	Diabody	RCP: >93.5%
	Apoptotic cells	Annexin V	RCY: 20–70%	[99,100]
		Annexin V	RCY: 6–12%	[101,102,103]
		Annexin V	RCP: 95%	[101,102,103]
		MBP-Annexin V		[104]
	CD44v6	cMAb U36	RCY: 72%	[105,106]
	positive cells		RCP: >97%
	positive cells		A_S: 32.6 MBq/mg
	squamous cell
	carcinoma
	CEA	Anti-CEA	RCY: 33–88%	[107]
	CEA	mini- and diabodies	RCY: 33–88%	[107]
CAT-method	Apoptotic cells	Annexin V	RCY: 4-6%,	[103]
			RCP: >99%,
			A_S: 8.6 GBq/µmol
	Human glioma	3F8 mAb	RCY: >90%	[108,109,110]
		A33 mAb	RCY: 55%	[110]
	Colon cancer	huA33 mAb	RCY: 40%,	[111]
			RCP >98%,
			A_S: 7.4 MBq/mg
	CEA	mAb CE-25,	RCY: 70–80%,	[112]
	CEA	CE 4-8-13	RCY: 70–80%,	[112]
	Ovarian cancer	MX35 or MH99	RCY: >87%	[113]
NBS-method	Breast cancer	C-erbB2	RCY: 96%	[114]
NBS-method	Breast cancer	HMFG1		[115]

RCY = radiochemical yield; RCP = radiochemical purity; A_S = specific activity.

4.3.2. ¹²⁴I-labeled prosthetic groups for radiolabeling of peptides and proteins

Various prosthetic groups have been developed for radiolabeling peptides and proteins with radioiodine, including ¹²⁴I. Prominent examples are the Bolton-Hunter reagent N-succinimidyl 3-(4-hydroxy-5-[¹²⁴I]iodophenyl) propionate ([¹²⁴I]I-SHPP,) succinimidyl-3-[¹²⁴I]iodobenzoate (3-[¹²⁴I]SIB) and succinimidyl-4-[¹²⁴I]iodobenzoate (4-[¹²⁴I]SIB).

¹²⁴I-labeled Bolton-Hunter reagent [¹²⁴I]I-SHPP was used for labelling an antibody VG76e targeting VEGFR to monitor therapy that relies on the VEGF pathway (Scheme 13) [116].

Scheme 13. Synthesis of [¹²⁴I]SHPP and radiolabeling of VG76e: a) [¹²⁴I]NaI, Iodogen^® (pH 6.5); b) VG76e, pH 8.5, 0 ºC.

The Bolton-Hunter reagent was first introduced by Bolton and Hunter in 1972 to copy iodo-tyrosyl residues as observed for the direct labeling of tyrosyl residues with radio-iodine. The Bolton-Hunter reagent reacts with lysine residues of peptides or proteins. It is more stable towards radio-deiodination.

Synthesis of [¹²⁴I]I-SHPP was carried out by incubating SHPP with a mixture of [¹²⁴I]NaI in HCl and sodium phosphate buffer (pH 6.5) in a Reacti-vial™ coated with Iodogen^®. After 1 min the solution was transferred into a second Reacti-vial™ containing anhydrous benzene-DMF (40:1) to quench the reaction. The organic layer was removed and dried by passing through a Pasteur pipette containing sodium sulphate. The sodium sulphate was washed with benzene to extract the additional product. The radiochemical yield of [¹²⁴I]I-SHPP was 25–58%.

The VG76e was diluted in sodium borate buffer (pH 8.5) and incubated with [¹²⁴I]I-SHPP for 1 h at 0 ºC. Radiolabeled antibody was purified by gel filtration. The average radiochemical yield of [¹²⁴I]I-SHPP-VG76e was 16.3 ± 8.7% with an specific activity of 11.1 GBq/µmol. PET images of HT1080-26.6 tumor-bearing mice clearly showed accumulation of the radiotracer in the tumor. The best contrast was achieved 24 h p.i. [116,117].

[¹²⁴I]I-SHPP was used for the radiolabeling of a anti-HER2 diabody for PET imaging of HER2-positive tumors [98]. The diabody was labeled directly according to the Iodogen^® method and indirectly using Bolton-Hunter reagent [¹²⁴I]I-SHPP. Direct radioiodination afforded the ¹²⁴I-labeled diabody in radiochemical yields of 14–19% at a specific activity of 33–102 MBq/mg. Indirect radiolabeling by means of [¹²⁴I]I-SHPP yield resulted in radiochemical yields of 6–8%. The specific activity was 37–46 MBq/mg.

In vivo studies revealed a higher tendency of radio-deiodination and subsequent radioactivity accumulation in the thyroid and stomach in the case of directly radioiodinated diabody. However, the metabolically more stable Bolton-Hunter conjugated diabody showed reduced immunoreactivity compared to the diabody prepared via direct radioiodination. The reduced immunoreactivity did not prevent PET imaging of HER2-expressing tumors [98].

JAA-F11 antibody used to localise Thomsen-Friedenreich alpha-linked antigen (TF-Ag) in vivo was labeled with [¹²⁴I]I-SHPP for imaging of breast cancer metastases [118]. The antibody was also labeled according to the Iodogen^® method to afford the radiolabeled antibody in radiochemical yields of 20%. The directly radiolabeled antibody showed diminished immunoactivity compared with the antibody labeled by means of a prosthetic group ([¹²⁴I]I-SHPP). Indirect labeling using Bolton-Hunter reagent [¹²⁴I]I-SHPP was achieved in radiochemical yields of 30%. The specific activity was determined to be 57 MBq/mg. Biodistribution studies showed uptake of the radiotracer in TF-AG positive tumors [118].

Various antibodies were labeled using the prosthetic group [¹²⁴I]SIB. Synthesis of the prosthetic groups 3-[¹²⁴I]SIB and 4-[¹²⁴I]SIB was reported by Koziorowski et al. (Figure 2) [119]. This synthesis is based on a radio-destannylation reaction starting from the corresponding trimethylstannyl precursor using Iodogen^® or iodobeads as the oxidizing agent.

Figure 2. Structures of 4-[¹²⁴I]SIB and 3-[¹²⁴I]SIB.

Collingridge et al. [101] and Glaser et al. [102] published iodine-124 labelling of annexin V using m-[¹²⁴I]SIB as a prosthetic group. Annexin V, a 36 kDa protein, is used to measure apoptosis in histopathology. An increasing number of reports also deal with radiolabeled annexin V as molecular probe for imaging apoptosis in vivo. Annexin V has been labeled with various radioiodine isotopes like iodine-125, -131 and -123. Radiolabeling with iodine-124 provides radiolabeled annexin V suitable for PET imaging.

Direct labeling of annexin V with [¹²⁴I]NaI and chloramine T as the oxidizing agent gave ¹²⁴I-labeled annexin V in radiochemical yields of 22.3 ± 2.6%. Indirect labeling of annexin V involved coupling with 3-[¹²⁴I]SIB, and the radiochemical yield of ¹²⁴I-labeled annexin V was 34% (Scheme 14) [101,102,103].

Scheme 14. Labeling of Annexin V with 3-[¹²⁴I]SIB.

Prosthetic group 4-[¹²⁴I]SIB was also used for the radiolabeling of annexin V (Scheme 15) [104]. The radiochemical yield was 20–30%.

Scheme 15. Labeling of a peptide/protein with 4-[¹²⁴I]SIB.

The indirectly radiolabeled annexin V (with 3-[¹²⁴I]SIB or 4-[¹²⁴I]SIB) showed higher in vivo stability when compared with the directly labelled annexin V. However, conjugation of annexin V with 3-[¹²⁴I]SIB or 4-[¹²⁴I]SIB resulted in an increased radioactivity accumulation in the kidneys. Therefore, directly labeled ¹²⁴I annexin V seems to be more suitable for PET imaging of apoptosis in vivo [104].

5. Summary and Conclusions

The present review has summarized the application of ¹²⁴I as a PET radionuclide for molecular imaging. Over the last four decades, radioiodinated radiopharmaceuticals have played an important role in nuclear medicine. The rapidly growing field of molecular imaging has stimulated research on novel positron-emitting radionuclides, especially with longer half-lives. The positron-emitting radiohalogen ¹²⁴I with its 4.2 d half-life is particularly attractive for in vivo detection and quantification of longer term biological and physiological processes. The long half-life of ¹²⁴I is especially suited for in vivo studies of the prolonged time course of uptake of higher molecular weight compounds like monoclonal antibodies (MAbs) in solid tumors. Moreover, the long half-life allows serial scanning protocols over a period of several days.

Recent advances in radionuclide production (targetry and target processing) allow the convenient production of sufficient quantities of ¹²⁴I on small biomedical cyclotrons for molecular imaging purposes. Radioiodination chemistry with ¹²⁴I relies on established radioiodine labeling methods, which can be subdivided into nucleophilic and electrophilic substitution reactions. The ease of oxidizing iodide into electropositive iodine species make electrophilic labeling methods the most frequently employed radioiodination technique. Over the last decade, numerous small molecules and larger compounds like proteins and antibodies have been successfully labeled with ¹²⁴I.

The future advances in probe development will lead to the development of novel innovative radiopharmaceuticals for specific molecular targeting for both imaging and therapy. The favorable 4.2 d half-life, the ease of production on widely available small medical cyclotrons, and the well-established radioiodine radiochemistry will make ¹²⁴I an important radiohalogen for future radiotracer development in the rapidly growing field of molecular imaging.

References

Weissleder, R.; Pittet, M.J. Imaging in the era of molecular oncology. Nature 2008, 452, 580–589. [Google Scholar] [CrossRef]
Blasberg, R.G. Molecular imaging and cancer. Mol. Cancer Ther. 2003, 2, 335–343. [Google Scholar]
Palladino, F.; Canadè, A.; Bianchi, A.; Lesti, G.; Antoniol, O.M.; Macis, G.; Marano, P. Molecular imaging: state of the art. Rays 2003, 28, 45–61. [Google Scholar]
Phelps, M.E. PET: the merging of biology and imaging into molecular imaging. J. Nucl. Med. 2000, 41, 661–681. [Google Scholar]
Phelps, M.E. Inaugural article: positron emission tomography provides molecular imaging of biological processes. Proc. Natl. Acad. Sci. USA 2000, 97, 9226–9233. [Google Scholar] [CrossRef]
Paans, A.M.; van Waarde, A.; Elsinga, P.H.; Willemsen, A.T.; Vaalburg, W. Positron emission tomography: the conceptual idea using a multidisciplinary approach. Methods 2002, 27, 195–207. [Google Scholar] [CrossRef]
Willemsen, A.T.; van den Hoff, J. Fundamentals of quantitative PET data analysis. Curr. Pharm. Des. 2002, 16, 1513–1526. [Google Scholar]
van den Hoff, J. Principles of quantitative positron emission tomography. Amino Acids 2005, 29, 341–353. [Google Scholar] [CrossRef]
Welch, M.J.; Laforest, R.; Lewis, J.S. Production of non-standard PET radionuclides and the application of radiopharmaceuticals labeled with these nuclides. Ernst Schering Res. Found. Workshop 2007, 62, 159–181. [Google Scholar]
McQuade, P.; Rowland, D.J.; Lewis, J.S.; Welch, M.J. Positron-emitting isotopes produced on biomedical cyclotrons. Curr. Med. Chem. 2005, 12, 807–818. [Google Scholar] [CrossRef]
Fujibayashi, Y.; Suzuki, K.; Fukumura, T.; Mori, T.; Kasamatsu, S. Non-standard radionuclide production for PET in Japan. Q. J. Nucl. Med. Mol. Imaging 2008, 52, 140–144. [Google Scholar]
Lambrecht, R.M.; Sajjad, M.; Qureshi, M.A.; Al-Yanbawi, S.J. Production of iodine-124. J. Radioanal. Nucl. Chem. Lett. 1988, 127, 143–150. [Google Scholar]
Sharma, H.L.; Zweit, J.; Downey, S.; Smith, A.M.; Smith, A.G. Production of ¹²⁴I for positron emission tomography. J. Labelled Compd. Rad. 1988, 26, 165–167. [Google Scholar]
Firouzbakht, M.L.; Schlyer, D.J.; Finn, R.D.; Laguzzi, G.; Wolf, A.P. Iodine-124 production: excitation functions for the ¹²⁴Te(d,2n)¹²⁴I and ¹²⁴Te(d,3n)¹²³I reactions from 7 to 24 MeV. Nucl. Instrum. Meth. B 1993, 79, 909–910. [Google Scholar] [CrossRef]
Knust, E.J.; Weinreich, R. Yields and impurities in several production reactions for ¹²⁴I. In Proc. 7th Workshop on Targetry and Target Chemistry, Heidelberg, Germany, June 8–11, 1997; pp. 253–262.
Bastian, Th.; Coenen, H.H.; Qaim, S.M. Excitation functions of ¹²⁴Te(d,xn)^124,125I reactions from threshold up to 14 MeV: comparative evaluation of nuclear routes for the production of ¹²⁴I. Appl. Radiat. Isot. 2001, 55, 303–308. [Google Scholar] [CrossRef]
Scholten, B.; Kovács, Z.; Tárkányi, F.; Qaim, S.M. Excitation functions of ¹²⁴Te(p, xn)^124,123I reactions from 6 to 31 MeV with special reference to the production of ¹²⁴I at a small cyclotron. Appl. Radiat. Isot. 1995, 46, 255–259. [Google Scholar] [CrossRef]
Qaim, S.M.; Hohn, A.; Bastian, Th.; El-Azoney, K.M.; Blessing, G.; Spellerberg, S.; Scholten, B.; Coenen, H.H. Some optimization studies relevant to the production of high-purity ¹²⁴I and ^120gI at a small-sized cyclotron. Appl. Radiat. Isot. 2003, 58, 69–78. [Google Scholar] [CrossRef]
Glaser, M.; Mackay, D.B.; Ranicar, A.S.O.; Waters, S.L.; Brady, F.; Luthra, S.K. Improved targetry and production of iodine-124 for PET studies. Radiochim. Acta. 2004, 92, 951–956. [Google Scholar] [CrossRef]
Nye, J.A.; Avila-Rodriguez, M.A.; Nickles, R.J. Production of [¹²⁴I]-iodine on an 11 MeV cyclotron. Radiochim. Acta 2006, 94, 213–216. [Google Scholar] [CrossRef]
Sajjad, M.; Bars, E.; Nabi, H.A. Optimization of ¹²⁴I production via ¹²⁴Te(p,n)¹²⁴I reaction. Appl. Radiat. Isot. 2006, 64, 965–970. [Google Scholar] [CrossRef]
Weinreich, R; Knust, E.J. Quality control of ¹²⁴I. In Proc. 6th Workshop on Targetry and Target Chemistry, Vancouver, Canada, August 17–19, 1995; pp. 84–86.
2009. Available online: http://www.nndc.bnl.gov/).
Hohn, A.; Nortier, F.M.; Scholten, B.; van der Walt, T.N.; Coenen, H.H.; Qaim, S.M. Excitation functions of ¹²⁵Te(p,xn)-reactions from their respective thresholds up to 100 MeV with special reference to the production of ¹²⁴I. Appl. Radiat. Isot. 2001, 55, 149–156. [Google Scholar] [CrossRef]
Vaidyanathan, G.; Wieland, B.W.; Larsen, R.H.; Zweit, J.; Zalutsky, M.R. High-yield production of iodine-124 using the ¹²⁵Te(p,2n)¹²⁴I reaction. In Proc. 6th Workshop on Targetry and Target Chemistry, Vancouver, Canada, August 17–19, 1995; pp. 87–88.
Qaim, S.M.; Hohn, A.; Nortier, F.M.; Blessing, G.; Schroeder, I.W.; Scholten, B.; van der Walt, T.N; Coenen, H.H. Production of ¹²⁴I at small and medium sized cyclotrons. In Proc. 8th Workshop on Targetry and Target Chemistry, St. Louis, MO, June 23–26, 1999; pp. 131–133.
Kim, J.; Lee, J.S.; Lee, T.; Park, H.; Chun, K. Optimized studies for the production of ¹²⁴I and ⁶⁴Cu radioisotopes at KIRAMS. In Proc. 11th Workshop on Targetry and Target Chemistry, Cambridge, UK, August 28–31, 2006; pp. 58–62.
Zweit, J.; Bakir, M.A.; Ott, R.J.; Sharma, H.L.; Cox, M.; Goodall, R. Excitation functions of proton induced reactions in natural tellurium: Production of no-carrier added iodine-124 for PET applications. In Proc. 4th Workshop on Targetry and Target Chemistry, Villigen, Switzerland, September 9–12, 1991; pp. 76–78.
Scholten, B.; Spellerberg, S.; Hassan, K.F.; Qaim, S.M.; Coenen, H.H. Comparison of production routes of ¹²⁴I with emphasis on the ¹²⁴Te(p,n)¹²⁴I reaction. In Proc. 11th Workshop on Targetry and Target Chemistry, Cambridge, UK, August 28–31, 2006; pp. 90–91.
Scholten, B.; Takács, S.; Kovács, Z.; Tárkányi, F.; Qaim, S.M. Excitation functions of deuteron induced reactions on ¹²³Te: Relevance to the production of ¹²³I and ¹²⁴I at low and medium sized cyclotrons. Appl. Radiat. Isot. 1997, 48, 267–271. [Google Scholar]
Hassan, K.F.; Qaim, S.M.; Saleh, Z.A.; Coenen, H.H. Alpha-particle-induced reactions on ^natsb and ¹²¹sb with particular reference to the production of the medically interesting radionuclide ¹²⁴I. Appl. Radiat. Isot. 2006, 64, 101–109. [Google Scholar]
Hassan, K.F.; Qaim, S.M.; Saleh, Z.A.; Coenen, H.H. ³He-particle-induced reactions on ^natSb for production of ¹²⁴I. Appl. Radiat. Isot. 2006, 64, 409–413. [Google Scholar]
Nye, J.A.; Avila-Rodriguez, M.A.; Nickles, R.J. A new binary compound for the production of ¹²⁴I via the ¹²⁴Te(p,n)¹²⁴I reaction. Appl. Radiat. Isot. 2007, 65, 407–412. [Google Scholar] [CrossRef]
Čomor, J.J.; Stevanović, Ž.; Rajčević, M.; Košutić, D. Modeling of thermal properties of a TeO₂ target for radioiodine production. Nucl. Instrum. Meth. A. 2004, 521, 161–170. [Google Scholar] [CrossRef]
Kudelin, B.K.; Gromova, E.A.; Gavrilina, L.V.; Solin, L.M. Purification of recovered tellurium dioxide for re-use in iodine radioisotope production. Appl. Radiat. Isot. 2001, 54, 383–386. [Google Scholar]
Runz, A.; Wolber, G.; Eisenhut, M.; Semmler, W. The production of I-121 at the vertical beam-line of the MC32NI cyclotron at the DKFZ Heidelberg. In Proc. 9th Workshop on Targetry and Target Chemistry, Turku, Finland, May 23–25, 2002; pp. 64–66.
Sheh, Y.; Koziorowski, J.; Balatoni, J.; Lom, C.; Dahl, J.R.; Finn, R.D. Low energy cyclotron production and chemical separation of “no carrier added” iodine-124 from a reusable, enriched tellurium-124 dioxide/aluminum oxide solid solution target. Radiochim. Acta 2000, 88, 169–173. [Google Scholar] [CrossRef]
Brown, D.J.; Mckay, D.B.; Coleman, J.; Luthra, S.K.; Brady, F.; Waters, S.L.; Pike, V.W. A facility for the safe recovery of high activities of iodine-124 produced by the ¹²⁴Te(p,n)¹²⁴I reaction. In Proc. 8th Workshop on Targetry and Target Chemistry, St. Louis, MO, 1999; pp. 134–136.
Der, B.; Sader, J.; McQuarrie, S.; Wilson, J. Heat modeling of water cooled target plates. In Proc. 11th Workshop on Targetry and Target Chemistry, Cambridge, August 28–31, 2006; pp. 20–21.
Gagnon, K.; Avila-Rodriguez, M.A.; McQuarrie, S.A. Thermal modeling of an ¹²⁴I solid cyclotron target. In Proc. 12th Workshop on Targetry and Target Chemistry, Seattle, WA, USA, July 21–24, 2008; p. 44.
Avila-Rodriguez, M.A.; Sader, J.A.; McQuarrie, S.A. 3D modeling and simulation of the thermal performance of solid cyclotron targets. In Proceedings of the COMSOL Conference, Genoble, France, 23-27 October 2007; pp. 359–363.
Rajec, P.; Reich, M.; Szöllős, O.; Baček, D.; Vlk, P.; Kováč, P.; Čomor, J.J. Production of ¹²⁴I on an 18/9 MeV cyclotrone. In Proc. 7th International conference on nuclear and radiochemistry, Budapest, Hungary, August 24–29; 2008. [Google Scholar]
Nye, J.A.; Dick, D.W.; Avila-Rodriguez, M.A.; Nickles, R.J. Radiohalogen targetry at the University of Wisconsin. Nucl. Instrum. Meth. B. 2005, 241, 693–696. [Google Scholar] [CrossRef]
Standardized high current solid targets for cyclotron production of diagnostic and therapeutic radionuclides. In IAEA Technical Report Series No. 432; IAEA: Vienna, Austria, 2004.
McCarthy, T.J.; Laforest, R.; Downer, J.B.; Lo, A.-R.; Margenau, W.H.; Hughey, B.; Shefer, R.E.; Klinkowskein, R.E.; Welch, M.J. Investigation of I-124, Br-76, and Br-77 production using a small biomedical cyclotron –Can induction furnaces help in the preparation and separation of targets? In Proc. 8th Workshop on Targetry and Target Chemistry, St. Louis, MO, USA, June 23–26, 1999; pp. 127–130.
Rowland, D.J.; Laforest, R.; McCarthy, T.J.; Hughey, B.J.; Welch, M.J. Conventional and induction furnace distillation procedures for the routine production of Br-76,77 and I-124 on disk and slanted targets. J. Labelled Compd. Rad. 2001, 44 Suppl. 1. [Google Scholar]
Sadeghi, M.; Dastan, M.; Ensaf, M.R.; Tehrani, A.A.; Tenreiro, C.; Avila, M. Thick tellurium electrodeposition on nickel-coated copper substrate for ¹²⁴I production. Appl. Radiat. Isot. 2008, 66, 1281–1286. [Google Scholar] [CrossRef]
Al-Yanbawi, S.; Melibari, S.; Al-Otabi, F.; Rahma, S.; Al Jammaz, I. Standardized high current solid Te-124 targets for cyclotron production of diagnostic radionuclides. In Proc. 11th Workshop on Targetry and Target Chemistry, Cambridge, UK, August 28–31, 2006; p. 1.
Van den Bosch, R.; De Goeij, J.J.M.; van der Heide, J.A.; Tertoolen, J.F.W.; Theelen, H.M.J.; Zegers, C. A new approach to target chemistry for the iodine-123 production via the ¹²⁴Te(p,2n) reaction. Int. J. Appl. Radiat. Isot. 1977, 28, 255–261. [Google Scholar] [CrossRef]
Alekseev, I.E.; Darmograi, V.V.; Marchenkov, N.S. Development of diffusion-thermal methods for preparing ⁶⁷Cu and ¹²⁴I for radionuclide therapy and positron emission tomography. Radiochemistry 2005, 47, 460–466. [Google Scholar]
Knust, E.J.; Dutschka, K.; Weinreich, R. Preparation of ¹²⁴I solutions after thermodistillation of irradiated ¹²⁴TeO₂ targets. Appl. Radiat. Isot. 2000, 52, 181–184. [Google Scholar] [CrossRef]
Weinreich, R.; Knust, E.J. Quality assurance of iodine-124 produced via the nuclear reaction ¹²⁴Te(d,2n)¹²⁴I. J. Radioanal. Nucl. Chem. Lett. 1996, 213, 253–261. [Google Scholar] [CrossRef]
Stevenson, N.R.; Buckley, K.; Gelbart, W.Z.; Hurtado, E.T.; Johnson, R.R.; Ruth, T.J.; Zeisler, S.K. On-line production of radioiodines with low energy accelerators. In Proc. 6th Workshop on Targetry and Target Chemistry, Vancouver, Cananda, August 17–19, 1995; pp. 82–83.
Zyuzin, A.; Johnson, R.; van Lier, E. Production and extraction of radioiodine isotopes using low melting temperature tellurium alloys. In Proc. 11th Workshop on Targetry and Target Chemistry, Cambridge, UK, August 28–31, 2006; pp. 128–129.
Johnson, R.R.; Watt, R.; Kovac, B.; Zyuzin, A.; Van Lier, E.; Erdman, K.L.; Gyles, Wm.; Sabaiduc, V.; McQuarrie, S.A.; Wilson, J.; Backhouse, C.; Gelbart, Wm.; Kuo, T. Advances in intense beams, beam delivery, targetry, and radiochemistry at advanced cyclotron systems. Nucl. Instrum. Meth. B. 2007, 261, 803–808. [Google Scholar] [CrossRef]
Oberdorfer, F.; Hellus, F.; Maier-Borst, W. Experiences in the routine production of ¹²³I via the ¹²⁴Te(p,2n)¹²³I reaction with a low energy cyclotron. J. Radioanal. Chem. 1981, 65, 51–56. [Google Scholar] [CrossRef]
Ylimaki, R.J.; Kiselev, M.Y.; Čomor, J.J.; Beyer, G.-J. Development of target delivery and recovery system for commercial production of high purity iodine-124. In Proc. 10th Workshop on Targetry and Target Chemistry, Madison, WI, USA, August 13–15, 2004.
Pentlow, K.S.; Graham, M.C.; Lambrecht, R.M.; Cheung, N.-K.V.; Larson, S.M. Quantitative imaging of I-124 using positron emission tomography with applications to radioimmunodiagnosis and radioimmunotherapy. Med. Phys. 1991, 18, 357–366. [Google Scholar] [CrossRef]
Beattie, B.J.; Finn, R.D.; Rowland, D.J.; Pentow, K.S. Quantitative imaging of bromine-76 and yttrium-86 with PET: A method for the removal of spurious activity introduced by cascade gamma rays. Med. Phys. 2003, 30, 2410–2423. [Google Scholar] [CrossRef]
Vandenberghe, S. Three-dimensional positron emission tomography imaging with ¹²⁴I and ⁸⁶Y. Nucl. Med. Commun. 2006, 27, 237–245. [Google Scholar] [CrossRef]
Lubberink, M.; Schneider, H.; Bergström, M.; Lundqvist, H. Quantitative imaging and correction for cascade gamma radiation of ⁷⁶Br with 2D and 3D PET. Phys. Med. Biol. 2002, 47, 3519–3534. [Google Scholar]
Sandström, M.; Tolmachev, V.; Kairemo, K.; Lundqvist, H.; Lubberink, M. Performance of coincidence imaging with long-lived positron emitters as an alternative to dedicated PET and SPECT. Phys. Med. Biol. 2004, 49, 5419–5432. [Google Scholar] [CrossRef]
Laforest, R.; Liu, X. Cascade removal and microPET imaging with ⁷⁶Br. Phys. Med. Biol. 2009, 54, 1503–1531. [Google Scholar] [CrossRef]
Lubberink, M.; van Schie, A.; de Jong, H.W.A.M.; van Dongen, G.A.M.S.; Teule, G.J.J. Acquisition settings for PET of ¹²⁴I administered simultaneously with therapeutic amounts of ¹³¹I. J. Nucl. Med. 2006, 47, 1375–1381. [Google Scholar]
Gregory, R.A.; Hooker, C.A.; Partridge, M.; Flux, G.D. Optimization and assessment of quantitative ¹²⁴I imaging on a Philips Gemini dual GS PET/CT system. Eur. J. Nucl. Med. Mol. Imaging 2009, 36, 1037–1048. [Google Scholar]
Trotter, D.E.G.; Manjeshwar, R.M.; Doss, M.; Shaller, C.; Robinson, M.K.; Tandon, R.; Adams, G.P.; Alder, L.P. Quantitation of small-animal ¹²⁴I activity distributions using a clinical PET/CT scanner. J. Nucl. Med. 2004, 45, 1237–1244. [Google Scholar]
Liu, X.; Laforest, R. Quantitative small animal PET imaging with nonconventional nuclides. Nucl. Med. Biol. 2009, 36, 551–559. [Google Scholar] [CrossRef]
Adam, M.J.; Wilbur, D.S. Radiohalogens for imaging and therapy. Chem. Soc. Rev. 2005, 34, 153–163. [Google Scholar]
Seevers, R.H.; Counsell, R.E. Radioiodination techniques for small organic molecules. Chem. Rev. 1982, 82, 575–590. [Google Scholar]
Moroz, M.A.; Serganova, I.; Zanzonico, P.; Ageyeva, L.; Beresten, T.; Dyomina, E.; Burnazi, E.; Finn, R.D.; Doubrovin, M.; Blasberg, R.G. Imaging hNET reporter gene expression with ¹²⁴I-MIBG. J. Nucl. Med. 2007, 48, 827–836. [Google Scholar] [CrossRef]
Reischl, G.; Dorow, D.S.; Cullinane, C.; Katsifis, A.; Roselt, P.; Binns, D.; Hicks, R.J. Imaging of tumor hypoxia with [¹²⁴I]IAZA in comparison with [¹⁸F]FMISO and [¹⁸F]FAZA--first small animal PET results. J. Pharm. Pharm. Sci. 2007, 10, 203–211. [Google Scholar]
Zanzonico, P.; O'Donoghue, J.; Chapman, J.D.; Schneider, R.; Cai, S.; Larson, S.D.; Wen, B.X.; Chen, Y.C.; Finn, R.; Ruan, S.T.; Gerweck, L.; Humm, J.; Ling, C. Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning. Eur. J. Nucl. Med. 2004, 31, 117–128. [Google Scholar] [CrossRef]
Schneider, R.F.; Engelhardt, E.L.; Stobbe, C.C.; Fenning, M.C.; Chapman, J.D. The synthesis and radiolabeling of novel markers of tissue hypoxia of the iodinated azomycin nucleoside class. J. Label. Compd. Radiopharm. 1997, 39, 541–557. [Google Scholar] [CrossRef]
Riedl, C.C.; Brader, P.; Zanzonico, P.B.; Chun, Y.S.; Woo, Y.H.; Singh, P.; Carlin, S.; Wen, B.X.; Ling, C.C.; Hricak, H.; Fong, Y.M. Imaging hypoxia in orthotopic rat liver tumors with iodine 124-labeled iodoazomycin galactopyranoside PET. Radiology 2008, 248, 561–570. [Google Scholar] [CrossRef]
Riedl, C.C.; Brader, P.; Zanzonico, P.; Reid, V.; Woo, Y.; Wen, B.; Ling, C.C.; Hricak, H.; Fong, Y.; Humm, J.L. Tumor hypoxia imaging in orthotopic liver tumors and peritoneal metastasis: a comparative study featuring dynamic F-18-MISO and I-124-IAZG PET in the same study cohort. Eur. J. Nucl. Med. 2008, 35, 39–46. [Google Scholar]
Stahlschmidt, A.; Machulla, H.J.; Reischl, G.; Knaus, E.E.; Wiebe, L.I. Radioiodination of 1-(2-deoxy-beta-D-ribofuranosyl)-2,4-difluoro-5-iodobenzene (dRFIB), a putative thymidine mimic nucleoside for cell proliferation studies. Appl. Radiat. Isot. 2008, 66, 1221–1228. [Google Scholar]
Guenther, I.; Wyer, L.; Knust, E.J.; Finn, R.D.; Koziorowski, J.; Weinreich, R. Radiosynthesis and quality assurance of 5- I-124 Iodo-2 '-deoxyuridine for functional PET imaging of cell proliferation. Nucl. Med. Biol. 1998, 25, 359–365. [Google Scholar] [CrossRef]
Blasberg, R.G.; Roelcke, U.; Weinreich, R.; Beattie, B.; von Ammon, K.; Yonekawa, Y.; Landolt, H.; Guenther, I.; Crompton, N.E.A.; Vontobel, P.; Missimer, J.; Maguire, R.P.; Koziorowski, J.; Knust, E.J.; Finn, R.D.; Leenders, K.L. Imaging brain tumor proliferative activity with I-124 iododeoxyuridine. Cancer Res. 2000, 60, 624–635. [Google Scholar]
Kim, S.W.; Park, J.H.; Yang, S.D.; Hur, M.G.; Choi, C.W.; Yu, K.R. Synthesis and in vitro/vivo Evaluation of Iodine-123/124 Labelled Hypericin Derivatives. Bull. Korean Chem. Soc. 2008, 29, 2023–2025. [Google Scholar] [CrossRef]
Tjuvajev, J.G.; Finn, R.; Watanabe, K.; Joshi, R.; Oku, T.; Kennedy, J.; Beattie, B.; Koutcher, J.; Larson, S.; Blasberg, R.G. Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: A potential method for monitoring clinical gene therapy. Cancer Res. 1996, 56, 4087–4095. [Google Scholar]
Doubrovin, M.; Ponomarev, V.; Beresten, T.; Balatoni, J.; Bornmann, W.; Finn, R.; Humm, J.; Larson, S.; Sadelain, M.; Blasberg, R.; Tjuvajev, J.G. Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo. Proc. Natl. Acad. Sci. USA 2001, 98, 9300–9305. [Google Scholar]
Brust, P.; Haubner, R.; Friedrich, A.; Scheunemann, M.; Anton, M.; Koufaki, O.N.; Hauses, M.; Noll, S.; Noll, B.; Haberkorn, U.; Schackert, G.; Schackert, H.K.; Avril, N.; Johannsen, B. Comparison of F-18 FHPG and I-124/125 FIAU for imaging herpes simplex virus type 1 thymidine kinase gene expression. Eur. J. Nucl. Med. 2001, 28, 721–729. [Google Scholar]
Tjuvajev, J.G.; Avril, N.; Oku, T.; Sasajima, T.; Miyagawa, T.; Joshi, R.; Safer, M.; Beattie, B.; DiResta, G.; Daghighian, F.; Augensen, F.; Koutcher, J.; Zweit, J.; Humm, J.; Larson, S.M.; Finn, R.; Blasberg, R. Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res. 1998, 58, 4333–4341. [Google Scholar]
Akgun, E.; Portoghese, P.S.; Sajjad, M.; Nabi, H.A. Synthesis and I-124-labeling of m-iodophenylpyrrolomorphinan as a potential PET imaging agent for delta opioid (DOP) receptors. J. Label. Compd. Radiopharm. 2007, 50, 165–170. [Google Scholar] [CrossRef]
Pal, A.; Glekas, A.; Doubrovin, M.; Balatoni, J.; Beresten, T.; Maxwell, D.; Soghomonyan, S.; Shavrin, A.; Ageyeva, L.; Finn, R.; Larson, S.M.; Bornmann, W.; Gelovani, J.G. Molecular imaging of EGFR kinase activity in tumors with I-124-labeled small molecular tracer and positron emission tomography. Mol. Imaging Biol. 2006, 8, 262–277. [Google Scholar]
Mishani, E.; Abourbeh, G.; Rozen, Y.; Jacobson, O.; Laky, D.; Ben-David, I.; Levitzki, A.; Shaul, M. Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: potential PET bioprobes for molecular imaging of EGFR-positive tumors. Nucl. Med. Biol. 2004, 31, 469–476. [Google Scholar] [CrossRef]
Ortu, G.; Ben-David, I.; Rozen, Y.; Freedman, N.M.T.; Chisin, R.; Levitzki, A.; Mishani, E. Labeled EGFr-TK irreversible inhibitor (ML03): In vitro and in vivo properties, potential as PET biomarker for cancer and feasibility as anticancer drug. Int. J. Cancer 2002, 101, 360–370. [Google Scholar] [CrossRef]
Shaul, M.; Abourbeh, G.; Jacobson, O.; Rozen, Y.; Laky, D.; Levitzki, A.; Mishani, E. Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer. Bioorg. Med. Chem. 2004, 12, 3421–3429. [Google Scholar] [CrossRef]
Pandey, S.K.; Sajjad, M.; Chen, Y.H.; Pandey, A.; Missert, J.R.; Batt, C.; Yao, R.T.; Nabi, H.A.; Oseroff, A.R.; Pandey, R.K. Compared to Purpurinimides, the Pyropheophorbide Containing an Iodobenzyl Group Showed Enhanced PDT Efficacy and Tumor Imaging (I-124-PET) Ability. Bioconjug. Chem. 2009, 20, 274–282. [Google Scholar]
Veach, D.R.; Namavari, M.; Beresten, T.; Balatoni, J.; Minchenko, M.; Djaballah, H.; Finn, R.D.; Clarkson, B.; Gelovani, J.G.; Bornmann, W.G.; Larson, S.M. Synthesis and in vitro examination of I-124 -, I-125 - and I-131 -2-(4-iodophenylamino) pyrido 2,3-d pyrimidin-7-one radiolabeled Abl kinase inhibitors. Nucl. Med. Biol. 2005, 32, 313–321. [Google Scholar]
Berding, G.; Schneider, U.; Gielow, P.; Buchert, R.; Donnerstag, F.; Brandau, W.; Knapp, W.H.; Emrich, H.M.; Muller-Vahl, K. Feasibility of central cannabinoid CB1 receptor imaging with I-124 AM281 PET demonstrated in a schizophrenic patient. Psychiatry Res. 2006, 147, 249–256. [Google Scholar] [CrossRef]
Koehler, L.; Graf, F.; Bergmann, R.; Steinbach, J.; Pietzsch, J.; Wuest, F. Radiosynthesis and radiopharmacological evaluation of cyclin-dependent kinase 4 (Cdk4) inhibitors. Eur. J. Med. Chem. 2010, 45, 727–737. [Google Scholar]
Toogood, P.L.; Harvey, P.J.; Repine, J.T.; Sheehan, D.J.; VanderWel, S.N.; Zhou, H.R.; Keller, P.R.; McNamara, D.J.; Sherry, D.; Zhu, T.; Brodfuehrer, J.; Choi, C.; Barvian, M.R.; Fry, D.W. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J. Med. Chem. 2005, 48, 2388–2406. [Google Scholar]
VanderWel, S.N.; Harvey, P.J.; McNamara, D.J.; Repine, J.T.; Keller, P.R.; Quin, J.; Booth, R.J.; Elliott, W.L.; Dobrusin, E.M.; Fry, D.W.; Toogood, P.L. Pyrido 2,3-d pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4. J. Med. Chem. 2005, 48, 2371–2387. [Google Scholar]
Graf, F.; Koehler, L.; Kniess, T.; Wuest, F.; Mosch, B.; Pietzsch, J. Cell cycle regulation kinase Cdk4 as a potential target for tumor cell treatment and tumor imaging. J. Oncol. 2009, 106378, 1–12. [Google Scholar]
Glaser, M.; Collingridge, D.R.; Aboagye, E.O.; Bouchier-Hayes, L.; Brown, D.J.; Hutchinson, O.C.; Martin, A.; Price, P.; Luthra, S.K.; Brady, F. Preparation of [¹²⁴I]IBA-ANNEXIN-V as a potential PET probe for apoptosis. J. Label. Compd. Radiopharm. 2001, 44, S336–S338. [Google Scholar]
Iozzo, P.; Osman, S.; Glaser, M.; Knickmeier, M.; Ferrannini, E.; Pike, V.W.; Camici, P.G.; Law, M.P. In vivo imaging of insulin receptors by PET: preclinical evaluation of iodine-125 and iodine-124 labelled human insulin. Nucl. Med. Biol. 2002, 29, 73–82. [Google Scholar] [CrossRef]
Robinson, M.K.; Doss, M.; Shaller, C.; Narayanan, D.; Marks, J.D.; Adler, L.P.; Trotter, D.E.G.; Adams, G.P. Quantitative immuno-positron emission tomography imaging oil HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res. 2005, 65, 1471–1478. [Google Scholar]
Dekker, B.; Keen, H.; Shaw, D.; Disley, L.; Hastings, D.; Hadfield, J.; Reader, A.; Allan, D.; Julyan, P.; Watson, A.; Zweit, J. Functional comparison of annexin V analogues labeled indirectly and directly with iodine-124. Nucl. Med. Biol. 2005, 32, 403–413. [Google Scholar] [CrossRef]
Keen, H.G.; Dekker, B.A.; Disley, L.; Hastings, D.; Lyons, S.; Reader, A.J.; Ottewell, P.; Watson, A.; Zweit, J. Imaging apoptosis in vivo using I-124-annexin V and PET. Nucl. Med. Biol. 2005, 32, 395–402. [Google Scholar] [CrossRef]
Collingridge, D.R.; Glaser, M.; Osman, S.; Barthel, H.; Hutchinson, O.C.; Luthra, S.K.; Brady, F.; Bouchier-Hayes, L.; Martin, S.J.; Workman, P.; Price, P.; Aboagye, E.O. In vitro selectivity, in vivo biodistribution and tumour uptake of annexin V radiolabelled with a positron emitting radioisotope. Br. J. Cancer. 2003, 89, 1327–1333. [Google Scholar] [CrossRef]
Glaser, M.; Collingridge, D.R.; Aboagye, E.O.; Bouchier-Hayes, L.; Hutchinson, O.C.; Martin, S.J.; Price, P.; Brady, F.; Luthra, S.K. Iodine-124 labelled Annexin-V as a potential radiotracer to study apoptosis using positron emission tomography. Appl. Radiat. Isot. 2003, 58, 55–62. [Google Scholar] [CrossRef]
Glaser, M.; Brown, D.J.; Law, M.P.; Iozzo, P.; Waters, S.L.; Poole, K.; Knickmeier, M.; Camici, P.G.; Pike, V.W. Preparation of no-carrier-added I-124 A(14)-iodoinsulin as a radiotracer for positron emission tomography. J. Label. Compd. Radiopharm. 2001, 44, 465–480. [Google Scholar]
Dekker, B.; Keen, H.; Lyons, S.; Disley, L.; Hastings, D.; Reader, A.; Ottewell, P.; Watson, A.; Zweit, J. MBP-annexin V radiolabeled directly with iodine-124 can be used to image apoptosis in vivo using PET. Nucl. Med. Biol. 2005, 32, 241–252. [Google Scholar] [CrossRef]
Verel, I.; Visser, G.W.M.; Boerman, O.C.; van Eerd, J.E.M.; Finn, R.; Boellaard, R.; Vosjan, M.; Walsum, M.S.V.; Snow, G.B.; van Dongen, G. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother. Radiopharm. 2003, 18, 655–661. [Google Scholar] [CrossRef]
Verel, I.; Visser, G.W.M.; Vosjan, M.; Finn, R.; Boellaard, R.; van Dongen, G. High-quality I-124-labelled monoclonal antibodies for use as PET scouting agents prior to I-131-radioimmunotherapy. Eur. J. Nucl. Med. 2004, 31, 1645–1652. [Google Scholar] [CrossRef]
Sundaresan, G.; Yazaki, P.J.; Shively, J.E.; Finn, R.D.; Larson, S.M.; Raubitschek, A.A.; Williams, L.E.; Chatziioannou, A.F.; Gambhir, S.S.; Wu, A.M. I-124-labeled engineered Anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J. Nucl. Med. 2003, 44, 1962–1969. [Google Scholar]
Daghighian, F.; Pentlow, K.S.; Larson, S.M.; Graham, M.C.; Diresta, G.R.; Yeh, S.D.J.; Macapinlac, H.; Finn, R.D.; Arbit, E.; Cheung, N.K.V. Development of a methode to measure kinetics of radiolabeled monoclonal antibody in human tumor with applications to microdosimetry - Positron emission tomography studies of I-124 labeled 3F8 monoclonal-antibody in glioma. Eur. J. Nucl. Med. 1993, 20, 402–409. [Google Scholar]
Larson, S.M.; Pentlow, K.S.; Volkow, N.D.; Wolf, A.P.; Finn, R.D.; Lambrecht, R.M.; Graham, M.C.; Diresta, G.; Bendriem, B.; Daghighian, F.; Yeh, S.D.J.; Wang, G.J.; Cheung, N.K.V. PET scanning of iodine-124-3F8 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma. J. Nucl. Med. 1992, 33, 2020–2023. [Google Scholar]
Finn, R.; Cheung, N.K.V.; Divgi, C.; St. Germain, J.; Graham, M.; Pentlow, K.; Larson, S.M. Technical challenges associated with the radiolabeling of monoclonal-antibodies utilizing short-lived, positron emitting radionuclides. Int. J. Rad. Appl. Instrum. B 1991, 18, 9–13. [Google Scholar]
Lee, F.T.; Hall, C.; Rigopoulos, A.; Zweit, J.; Pathmaraj, K.; O'Keefe, G.J.; Smyth, F.E.; Welt, S.; Old, L.J.; Scott, A.M. Immune-PET of human colon xenograft-bearing BALB/c nude mice using I-124-CDR-grafted humanized A33 monoclonal antibody. J. Nucl. Med. 2001, 42, 764–769. [Google Scholar]
Westera, G.; Reist, H.W.; Buchegger, F.; Heusser, C.H.; Hardman, N.; Pfeiffer, A.; Sharma, H.L.; Vonschulthess, G.K.; Mach, J.P. Radioimmuno Positron Emission Tomography with monoclonal-antibodies - a new approach to quantifying invivo tumor concentrations and biodistribution for radioimmunotherapy. Nucl. Med. Commun. 1991, 12, 429–437. [Google Scholar] [CrossRef]
Rubin, S.C.; Kairemo, K.J.A.; Brownell, A.L.; Daghighian, F.; Federici, M.G.; Pentlow, K.S.; Finn, R.D.; Lambrecht, R.M.; Hoskins, W.J.; Lewis, J.L.; Larson, S.M. High-resolution positron emission tomography of human ovarian-cancer in nude rats using I-124 labeled monoclonal-antibodies. Gynecol. Oncol. 1993, 48, 61–67. [Google Scholar] [CrossRef]
Bakir, M.A.; Eccles, S.A.; Babich, J.W.; Aftab, N.; Styles, J.M.; Dean, C.J.; Ott, R.J. C-ERB2 protein overexpression in breast cancer as a target for PET using iodine-124-labeled monoclonal antibodies. J. Nucl. Med. 1992, 33, 2154–2160. [Google Scholar]
Wilson, C.B.; Snook, D.E.; Dhokia, B.; Taylor, C.V.J.; Watson, I.A.; Lammertsma, A.A.; Lambrecht, R.; Waxman, J.; Jones, T.; Epenetos, A.A. Quantitative measurement of monoclonel-antibody distribution and blood-flow using positron emission tomography and I-124 in patients with breast cancer. Int. J. Cancer 1991, 47, 344–347. [Google Scholar] [CrossRef]
Glaser, M.; Carroll, V.A.; Collingridge, D.R.; Aboagye, E.O.; Price, P.; Bicknell, R.; Harris, A.L.; Luthra, S.K.; Brady, F. Preparation of the iodine-124 derivative of the Bolton-Hunter reagent ( I-124 I-SHPP) and its use for labelling a VEGF antibody as a PET tracer. J. Label. Compd. Radiopharm. 2002, 45, 1077–1090. [Google Scholar] [CrossRef]
Collingridge, D.R.; Carroll, V.A.; Glaser, M.; Aboagye, E.O.; Osman, S.; Hutchinson, O.C.; Barthel, H.; Luthra, S.K.; Brady, F.; Bicknell, R.; Price, P.; Harris, A.L. The development of I-124 iodinated-VG76e: A novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res. 2002, 62, 5912–5919. [Google Scholar]
Chaturvedi, R.; Heimburg, J.; Yan, J.; Koury, S.; Sajjad, M.; Abdel-Nabi, H.H.; Rittenhouse-Olson, K. Tumor immunolocalization using I-124-iodine-labeled JAA-F11 antibody to Thomsen-Friedenreich alpha-linked antigen. Appl. Radiat. Isot. 2008, 66, 278–287. [Google Scholar] [CrossRef]
Koziorowski, J.; Henssen, C.; Weinreich, R. A new convenient route to radioiodinated N-succinimidyl 3- and 4-iodobenzoate, two reagents for radioiodination of proteins. Appl. Radiat. Isot. 1998, 49, 955–959. [Google Scholar] [CrossRef]

© 2010 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).

Share and Cite

MDPI and ACS Style

Koehler, L.; Gagnon, K.; McQuarrie, S.; Wuest, F. Iodine-124: A Promising Positron Emitter for Organic PET Chemistry. Molecules 2010, 15, 2686-2718. https://doi.org/10.3390/molecules15042686

AMA Style

Koehler L, Gagnon K, McQuarrie S, Wuest F. Iodine-124: A Promising Positron Emitter for Organic PET Chemistry. Molecules. 2010; 15(4):2686-2718. https://doi.org/10.3390/molecules15042686

Chicago/Turabian Style

Koehler, Lena, Katherine Gagnon, Steve McQuarrie, and Frank Wuest. 2010. "Iodine-124: A Promising Positron Emitter for Organic PET Chemistry" Molecules 15, no. 4: 2686-2718. https://doi.org/10.3390/molecules15042686

Article Menu

Iodine-124: A Promising Positron Emitter for Organic PET Chemistry

Abstract

1. Introduction

2. Production, processing, and PET imaging of 124I

2.1. 124I production routes

2.2. Thermal design and irradiation considerations

2.3. Processing: Dry distillation of the 124I

2.4. PET imaging of 124I

3. Basic Principles of Radiochemistry with Radioiodine Isotopes

3.1. Nucleophilic substitution reactions

3.2. Electrophilic substitution reactions

3.3. Radioiodination of peptides and proteins

4. Examples for 124I-labeled Compounds

4.1. 124I-labeled compounds prepared via nucleophilic exchange reactions

4.1.1. meta-[124I]Iodobenzylguanidine ([124I]MIBG)

4.1.2. 1-α-D-(5-deoxy-5-[124I]iodo-arabinofuranosyl)-2-nitroimidazole ([124I]IAZA)

4.1.3. [124I]Iodo-azomycin-galactopyranoside ([124I]IAZG)

4.1.4. 1-(2-Deoxy--β-D-ribofuranosyl)-2,4-difluoro-5-[124I]iodobenzene ([124I]dRFIB)

4.2. 124I-labeled compounds prepared via electrophilic substitution reactions

4.2.1. Direct electrophilic substitution on activated aromatic systems

4.2.1.1. 5-[124I]Iodo-2′-deoxyuridine ([124I]IUdR)

4.2.1.2. 124I-labeled hypericin

4.2.1.3. 2'-Fluoro-2'-deoxy-1-β-D-arabinofuranosyl-5-[124I]iodouracil ([124I]FIAU)

4.2.2. Electrophilic radioiodo-destannylation reactions

4.2.2.1. 124I-labeled m-iodophenylpyrrolomorphinan (m-[124I]IPPM)

4.2.2.2. [4-(3-[124I]iodoanilino)-quinazolin-6-yl]amide-(3-morpholino-4-ylpropyl)amide (mor-pholino-[124I]IPQA)

4.2.2.3. 124I-labeled 6-anilino-quinazoline derivatives as EGFR inhibitors

4.2.2.4. Synthesis of 124I-labeled purpurinimide derivatives

4.2.2.5. Synthesis of 124I-labeled 2-(4-iodophenylamino) pyrido[2,3-d]pyrimidin-7-one

4.2.2.6. Synthesis of n-(morpholin-4-yl)-1-(2,4-dichlorophenyl)-5-(4-[124I]iodophenyl)-4-methyl-1h-pyrazole-3-carboxamide ([124I]AM281)

4.2.2.7. Synthesis of 124I-labeled CDK4/6 inhibitors

4.3. Radioiodination of peptides and proteins

4.3.1. Direct labeling of peptides and proteins with 124I

4.3.2. 124I-labeled prosthetic groups for radiolabeling of peptides and proteins

5. Summary and Conclusions

References

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI

2. Production, processing, and PET imaging of ¹²⁴I

2.1. ¹²⁴I production routes

2.3. Processing: Dry distillation of the ¹²⁴I

2.4. PET imaging of ¹²⁴I

4. Examples for ¹²⁴I-labeled Compounds

4.1. ¹²⁴I-labeled compounds prepared via nucleophilic exchange reactions

4.1.1. meta-[¹²⁴I]Iodobenzylguanidine ([¹²⁴I]MIBG)

4.1.2. 1-α-D-(5-deoxy-5-[¹²⁴I]iodo-arabinofuranosyl)-2-nitroimidazole ([¹²⁴I]IAZA)

4.1.3. [¹²⁴I]Iodo-azomycin-galactopyranoside ([¹²⁴I]IAZG)

4.1.4. 1-(2-Deoxy--β-D-ribofuranosyl)-2,4-difluoro-5-[¹²⁴I]iodobenzene ([¹²⁴I]dRFIB)

4.2. ¹²⁴I-labeled compounds prepared via electrophilic substitution reactions

4.2.1.1. 5-[¹²⁴I]Iodo-2′-deoxyuridine ([¹²⁴I]IUdR)

4.2.1.2. ¹²⁴I-labeled hypericin

4.2.1.3. 2'-Fluoro-2'-deoxy-1-β-D-arabinofuranosyl-5-[¹²⁴I]iodouracil ([¹²⁴I]FIAU)

4.2.2.1. ¹²⁴I-labeled m-iodophenylpyrrolomorphinan (m-[¹²⁴I]IPPM)

4.2.2.2. [4-(3-[¹²⁴I]iodoanilino)-quinazolin-6-yl]amide-(3-morpholino-4-ylpropyl)amide (mor-pholino-[¹²⁴I]IPQA)

4.2.2.3. ¹²⁴I-labeled 6-anilino-quinazoline derivatives as EGFR inhibitors

4.2.2.4. Synthesis of ¹²⁴I-labeled purpurinimide derivatives

4.2.2.5. Synthesis of ¹²⁴I-labeled 2-(4-iodophenylamino) pyrido[2,3-d]pyrimidin-7-one

4.2.2.6. Synthesis of n-(morpholin-4-yl)-1-(2,4-dichlorophenyl)-5-(4-[¹²⁴I]iodophenyl)-4-methyl-1h-pyrazole-3-carboxamide ([¹²⁴I]AM281)

4.2.2.7. Synthesis of ¹²⁴I-labeled CDK4/6 inhibitors

4.3.1. Direct labeling of peptides and proteins with ¹²⁴I

4.3.2. ¹²⁴I-labeled prosthetic groups for radiolabeling of peptides and proteins